NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
i DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 NCI Protocol #:  N/a  
 DF/HCC Protocol #: 15-491  
 TITLE:   Phase II Study of ABT-199 (GDC-199) in  patients with relapsed or refractory 
Waldenström Macroglobulinemia 
   Coordinating Center:    
Dana-Farber Cancer Institute 
         [ADDRESS_508790]  
         [LOCATION_011], MA [ZIP_CODE] [LOCATION_003] 
 
*Principal Investigator (PI):  Jorge J. Castillo, MD 
 Dana-Farber Cancer Institute 
 [EMAIL_7710] 
 
 Other Investigators:  
Steven P. Treon, MD, PhD 
 Dana-Farber Cancer Institute 
 [EMAIL_7711] 
 
 Study Coordinator:  
Kirsten Meid Dana-Farber Cancer Institute [ADDRESS_508791] [LOCATION_011], MA [ZIP_CODE] [LOCATION_003] [EMAIL_7712]  
      Agent: BCL2 inhibitor ABT-199 (GDC-199)  
  IND #:  127663 
IND Sponsor:   Jorge J. Castillo, MD  
 Protocol Type / Version # / Version Date:  Original/ Version #10 1.18.18  
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
ii DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  
SCHEMA 
 
  
   
 
      
                         
 
      Screening 
Registration 
ABT-199 Administration 
Lead-in phase followed by 
26 four-week cycles (2 
years)  
Response Evaluation 
Stop ABT-199 
Event Monitoring for 2 
years Event Monitoring Progressive Disease 
(PD), Unacceptable 
Toxicity, No Response Stable Disease or Response 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
iii DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 TABLE OF CONTENTS 
 
SCHEMA ........................................................................................................................ ................ ii  
1.  OBJECTIVES .................................................................................................................... ..1 
1.1 Study Design ............................................................................................................1  
1.2 Primary Objectives ...................................................................................................2  
1.3 Secondary Objectives ...............................................................................................2  
2.  BACKGROUND .................................................................................................................2  
2.1 Study Disease(s).......................................................................................................2  
2.2 IND Agent ABT-199 ...............................................................................................4  
2.3 Rationale ..................................................................................................................7  
2.4 Correlative Studies Background ............................................................................10  
3.  PARTICIPANT SELECTION ...........................................................................................11  
3.1 Eligibility Criteria ..................................................................................................11  
3.2 Exclusion Criteria ................................................................................................12  
3.3 Inclusion of Wome n and Minorities ......................................................................12  
4.  REGISTRATION PROCEDURES ...................................................................................12  
4.1 General Guidelines for DF/HCC Institutions ........................................................13  
4.2 Registration Process for DF/HCC Institutions .......................................................13  
4.3 General Guidelines for Other Investigative Sites ..................................................13  
4.4 Registration Process for Ot her Investigative Sites .................................................13  
5.  TREATMENT PLAN ........................................................................................................14  
5.1 Treatment Regimen ................................................................................................14  
5.2 Pre-Treatment Criteria ...........................................................................................14  
5.3 Agent Administration .............................................................................................14  
5.4 General Concomitant Medication an d Supportive Care Guidelines ......................17  
5.5 Criteria for Taking a Particip ant Off Protocol Therapy .........................................20  
5.6 Duration of Follow Up ...........................................................................................21  
5.7 Criteria for Taking a Participant Off Study ...........................................................21  
6.  DOSING DELAYS/DOSE MODIFICATIONS................................................................21  
7.  ADVERSE EVENTS:  LIST AND RE PORTING REQUIREMENTS ............................23  
7.1 Expected Toxicities ................................................................................................23  
Tumor Lysis Syndrome......................................................................................................26  
7.2 Adverse Event Characteristics ...............................................................................31  
7.3 Expedited Adverse Event Reporting ......................................................................32  
7.4 Expedited Reporting to the Food and Drug Administration (FDA) ......................33  
7.5 Expedited Reporting to Hospi[INVESTIGATOR_52453] .............................................33  
7.6 Expedited Reporting to Abbvie Drug Safety Department .....................................33  
7.7 Routine Adverse Event Reporting .........................................................................34  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
iv DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508792] – Hematologic Tumors ..............................................................39  
12. DATA REPORTING / REGULATORY REQUIREMENTS ...........................................40  
12.1 Data Reporting .......................................................................................................41  
12.2 Data Safety Monitoring ..........................................................................................41  
12.3 Multicenter Guidelines ...........................................................................................41  
12.4 Collaborative Agreements Language .....................................................................42  
13. STATISTICAL CONSIDERATIONS...............................................................................42  
13.1 Study Design/Endpoints.........................................................................................42  
13.2 Sample Size, Accrual Rate and Study Duration ....................................................42  
13.3 Stratification Factors ..............................................................................................43  
13.4 Interim Monitoring Plan ........................................................................................43  
13.5 Analysis of Primary Endpoints ..............................................................................43  
13.6 Analysis of Secondary Endpoints ..........................................................................43  
13.7 Reporting and Exclusions ......................................................................................44  
14. PUBLICATION PLAN .....................................................................................................44  
REFERENCES .................................................................................................................... ..........45  
APPENDIX A   PERFORMANCE STATUS CRITERIA ..................................................47  
APPENDIX C.  dEFINITIONS OF LABO RATORY AND CLINICAL TUMOR LYSIS 
SYNDROME .....................................................................................................................5 2 
APPENDIX d   MULTICENTER GUIDELINES...............................................................53  
15. INTRODUCTION .............................................................................................................55  
15.1 Purpose ...................................................................................................................55  
15.2 Multi-Center Data and Safety Monitoring Plan Definitions ..................................55  
16. GENERAL ROLES AND RE SPONSIBILITIES .............................................................56  
16.1 DF/HCC Sponsor ...................................................................................................56  
16.2 Coordinating Center ...............................................................................................57  
16.3 Participating Institution ..........................................................................................57  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
v DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 17. DF/HCC REQUIREMENTS FOR MU LTI-CENTER PROTOCOLS..............................58  
17.1 Protocol Distribution ..............................................................................................58  
17.2 Protocol Revisions  and Closures ...........................................................................58  
17.3 Informed Consent Requirements ...........................................................................59  
17.4 IRB Documentation ...............................................................................................59  
17.5 IRB Re-Approval ...................................................................................................59  
17.6 Participant Confidentiality a nd Authorization Statement ......................................60  
17.7 DF/HCC Multi-Center Protoc ol Registration Policy .............................................60  
17.8 DF/HCC Protocol Case Number ............................................................................61  
17.9 Safety Assessments and Toxicity Monitoring .......................................................63  
17.10 Data Management ..................................................................................................63  
18. REQUISITIONING INVESTIGATIONAL DRUG..........................................................64  
19. MONITORING: QUALITY CONTROL ..........................................................................64  
19.1 Ongoing Monitoring of Protocol Compliance .......................................................64  
19.2 Monitoring Reports ................................................................................................65  
19.3 Accrual Monitoring ................................................................................................66  
20. AUDITING: QUALITY ASSURANCE ...........................................................................66  
20.1 Audit Plan: DF/HCC Sponsored Trials..................................................................66  
20.2 Audit Notification ..................................................................................................66  
20.3 Audit Reports .........................................................................................................66  
20.4 Participating Institution Performance ....................................................................66  
20.5 Corrective Actions .................................................................................................67  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
1 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  
1. OBJECTIVES 
 
1.1 Study Design 
 
This is a Phase II study designed to evaluate th e safety and efficacy of ABT-199 (GDC-199) in 
previously treated, relapsed/refractory WM patie nts. Treatment will be administered daily to 
participants with WM, and partic ipants will receive treatment for a duration of completion of the 
lead-in phase to the target dose level, followed by a maximum of [ADDRESS_508793] six patients enrolled  (Cohort 1), followed by [CONTACT_345040]-199 at 800 mg PO 
daily for 2 years following the completion of the lead-in phase. If no evidence of tumor lysis 
syndrome is seen, then starting with the sevent h patient (Cohort 2), the lead-in phase would 
consist on ABT-[ADDRESS_508794] scans will not be required if collected within 90 days prior to Cycle 1 Day 
1 visit. Clinical laboratory tests includi ng a complete blood count plus differential, 
comprehensive chemistry panel (electrolytes, BUN, creatinine, albumin, total protein, total 
bilirubin, SGOT (AST), SGPT (ALT), alkalin e phosphatase), magnesium, beta-2-microglobulin, 
serum and protein electrophoresis with quantific ation of immunoglobulins (IgM, IgG, IgA) and 
immunofixation studies, Von Willebrands factor, HIV, HBsAg, HBsAb, HBcAb and HCV 
antibody. Serum pregnancy tests for women of childbe aring potential will al so be performed at 
the Screening visit. Cryoglobulins and cold agglutinins will be obtained if clinically indicated. 
Coagulation studies (PT, PTT, PT-INR) and tu mor lysis laboratories (calcium, phosphorus, 
LDH, and uric acid) will also  be performed at baseline. 
 
Participants who meet the eligibility requireme nts as assessed at the Screening visit will be 
enrolled in the study and initiated on study drug. Pa rticipants will be evaluated for development 
of tumor lysis syndrome (TLS) on Days [ADDRESS_508795] throughout the l ead-in (Cycle 1) period. All patients will be 
encouraged to drink 2 L of fluid the day before starting ABT-199. Pati ents in whom oral intake is 
inadequate, 1 L of 0.9% normal saline will be ad ministered IV prior to first dose of ABT-[ADDRESS_508796] until week 2, as needed 
to reach the maximum dose of 800 mg PO daily. Pa tients with laboratory or  clinical evidence of 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
2 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 TLS will be hospi[INVESTIGATOR_403402] . The inpatient management of TLS, frequency 
of monitoring and duration of hospi[INVESTIGATOR_059] w ill be decided by [CONTACT_941] i nvestigator, aided by [CONTACT_403442] B (Recommendations for Initial Management of Electrolyte 
Abnormalities and Prevention of Tumor Lysis S yndrome [TLS]). In patients who developed 
TLS, hospi[INVESTIGATOR_403403] [ADDRESS_508797] day of each cycle (4 weeks ± 1 week) at cycle 2, and 3 
and thereafter every 3 cycles (12 weeks ± 2 weeks)  for the duration of therapy. Participants will 
be eligible to continue therapy for [ADDRESS_508798] discontinuation.  
 Response criteria updated at the Sixth International Work shop on Waldenström 
macroglobulinemia (Owen 2013) will be used to a ssess response, stable di sease, and progressive 
disease. Response outcomes to be determined wi ll include: Best overall response rate (including 
minor, partial, very good partial and complete response rate) and major response rate (including 
partial, very good partial and comp lete response rate), landmark anal ysis for 2 and 4-year overall 
survival (OS), progression-free survival (PFS)  and median duration of  response (DOR). The 
duration of therapy will depe nd on individual response, eviden ce of disease progression and 
tolerance of the drug. If at the end of study therapy, it is deemed  that WM patients derive benefit 
from ABT-199, [COMPANY_013] will work wi th the investigator to evaluate options for continuation of 
ABT-199. If ABT-[ADDRESS_508799] the option of receiving ABT-199  via prescription coverage. Follow-up will 
continue for 2 years or until new therapy afte r patients had stopped taking ABT-199 for any 
reason, except death.  1.2 
Primary Objectives 
 
 To assess the best overall response rate (O RR) of ABT-199 in symptomatic WM patients 
with relapsed/refractory disease. 
 1.3 
Secondary Objectives 
 To assess the safety and tolerability of ABT-199 in symptomatic WM patients with 
relapsed/refractory disease. 
 To evaluate the rate of CR, very good part ial response (VGPR), pa rtial response (PR), 
minimal response (MR), stable disease (SD) and progressive disease (PD). 
 To evaluate the 2-year and 4-years median OS, median PFS and median duration of response 
(DOR). 
 To evaluate the toxicity profile of ABT- 199 in patients with relapsed/refractory WM 
 To evaluate the association between pres ence of MYD88 and CXCR4 mutations and 
response to ABT-199 
 
2. BACKGROUND 
 
2.1 Study Disease(s) 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
3 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 WM is a rare B-cell lymphoproliferative disorder  characterized by [CONTACT_403443]-producing lymphoplasmacytic cells. Such  malignant cells accumulate in the bone 
marrow, liver, spleen and lymph nodes. WM is diagnosed by [CONTACT_403444][INVESTIGATOR_2531] (M-spi[INVESTIGATOR_2531]) identifie d in a serum protein 
electrophoresis (SPEP) (Swerdlow 2002). The incide nce of WM in the [LOCATION_002] (US) is 
approximately 0.3 per 100,000 persons per year accounting for approximately 1000 new cases 
per year (Sekhar 2012), although this is likely to be an underestim ation. The clinical course of 
WM is variable and although patients might experi ence an overall survival (OS) measured in 
decades (Castillo 2014), WM remains incurable w ith current therapeutic regimens (Treon 2009). 
Hence, the disease course is characterized by [CONTACT_403445], each harder to treat than the 
previous one. Additionally, many of  the disabling symptoms associated with the disease, such as 
hyperviscosity, fatigue, anemia or neuropathy, can be exacerbated by [CONTACT_48831]. Rituximab can 
induce disabling IgM flare (Tre on 2002), alkylating agents an d nucleoside analogs can be 
associated with the development of seconda ry MDS/AML (Leleu 2009), bortezomib can cause 
high rates of peripheral neuropathy (Treon 2009), and carfilzomib can induce severe 
hypogammaglobulinemia (Treon 2014). Hence, the careful evaluation of agents with novel 
mechanisms of action is needed to improve the quality of life (QOL), and response and survival 
rates in patients with WM.  Recently, our group identified a recurrent mutatio n in the MYD88 gene (MYD88 L265P), which 
is seen in over 90% of cases with WM (Treon 2012). The occurrenc e of this mutation in WM has 
since been validated in several independent cohorts. In contrast, the MYD88 L265P gene 
mutation was not detected in patients with IgM myeloma, and was detected in less than 10% of 
patients with marginal zone lymphoma. The hi gh specificity and sens itivity of the MYD88 
L265P gene mutation has obvious diagnostic implic ations in patients in whom a diagnosis of 
WM is suspected but uncertain. The MYD88 L265P  gene mutation has shown to support growth 
and survival of WM cells in several studies . A knockdown model of MYD88 showed decreased 
survival of MYD88 L265P expressing WM cells , whereas survival was more enhanced by 
[CONTACT_403446]-in of mutant versus  wild-type MYD88. MYD88 acts as an  adaptor molecule in toll-like 
receptor (TLR) and interleukin-1 receptor (I L-1R) signaling. Following stimulation of TLR or 
IL-1R, MYD88 is recruited to the activated r eceptor complex as a homodimer which complexes 
with IL-1R-associated kinase 4 (IRAK4) and subsequently activates IRAK1 and IRAK2. IRAK1 
activation then leads to NF- κB activation via I κBα phosphorylation. Recently, a study has shown 
that MYD88 L265P also activates the Bruton’s Tyrosine Kinase (BTK) pathway (Yang 2013). In 
this pre-clinical study, the activation of BTK by [CONTACT_403447]88 coul d be abrogated by [CONTACT_403448]. Clinically, the use of the oral BTK inhibitor ibru tinib has shown to be effective 
in patients with WM (Treon 2013). A phase II stud y on 63 patients with relapsed/refractory WM 
was performed evaluating ibrutinib at a dose of 420 mg PO once daily. The ORR was 
approximately 80% with relatively well-tolerated  AE profile. The median time to response (IgM 
level decrease by [CONTACT_2669] 25% of baseline) was 4 weeks. At a median follow-up of 18 months, 
80% of patients continue on ibrutinib.  Another study from our group reported the o ccurrence of recurrent somatic CXCR4 gene 
mutations in approximately 30% of WM patients (Hunter 2013). The somatic  mutations occur in 
the C-terminal domain, and are similar to thos e observed in patients with WHIM (Warts, 
Hypogammaglobulinemia, Infections, and Myelokath exis) syndrome. These mutations regulate 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
4 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 signaling of CXCR4 by [CONTACT_403449]-1a. In WM  patients, two classes of CXCR4 mutations 
occur: non-sense (CXCR4WHIM/NS) and frameshift (CXCR4WHIM/FS) mutations. Non-sense and 
frameshift mutations are almost equally divide d among WM patients, and over [ADDRESS_508800] been associated with resistance to ibrutinib (Cao 2014). In the 
phase II study of ibrutinib in  relapsed/refractory WM patie nts, patients carrying CXCR4 
mutations had lower rates of response and lowe r depth of response to ibrutinib (Treon 2014). 
Hence, there is an unmet need for more effec tive, better-tolerated drugs for patients with WM. 
 
2.2 IND Agent ABT-199  
 
ABT-199 (GDC-0199) is a novel, orally bioavailab le, small-molecule B-cell lymphoma-2 (Bcl-
2) family inhibitor in the bi arylacylsulfonamide chemical class. ABT-199 binds with high 
affinity (inhibition constant [Ki] < 0.010 nM) to  antiapoptotic protein Bcl-2 and with lower 
affinity to other antiapoptotic Bcl-2 family pr oteins, like Bcl-XL and Bcl-w (> 4,000-fold and > 
2,000- to > 20,000-fold lower affinity than to Bcl-2, respectively). 
 Antiapoptotic Bcl-2 family memb ers are associated with tumo r initiation, disease progression, 
and chemotherapy resistance, as well as auto immunity. Overexpression of Bcl-2 is a major 
contributor to the pathogenesis  of some lymphoid malignancies;  antagonism of the action of 
these proteins may enhance response to ther apy and overcome resistance, and thus, these 
proteins are compelling targets for anti-tumor therapy (Fesik 2 005). Currently, [COMPANY_013], Inc. and 
Genentech/[COMPANY_002] are investigating ABT-[ADDRESS_508801] patient -derived chronic lymphocytic 
leukemia (CLL) and acute myeloid leukemia (A ML) cells and a variet y of lymphoma and 
leukemia cell lines, including B-cell follicula r lymphomas (FLs), mantle cell lymphomas 
(MCLs), diffuse large B –cell lymphomas (D LBCLs), AMLs, and multiple myeloma (MM). 
ABT-[ADDRESS_508802] non-Hod gkin lymphoma (NHL) cell lines expressing 
high levels of Bcl-2.  ABT-199 inhibits subcutaneous xe nograft growth of human tumor cell lines derived from acute 
lymphoblastic leukemia (ALL), NHL, and AML, a nd is highly efficacious using various doses 
and combined with other regimens. The drug is also active in a model of disseminated ALL and 
AML. ABT-[ADDRESS_508803] va riety of chemotherapeutic agents in other 
human hematological models. Specifically, ABT- 199 enhances the efficacy of bendamustine and 
rituximab (BR) in models of MCL and DLBCL. Furthermore, ABT-199 demonstrated potential 
to enhance the efficacy of bortezomib in multiple models of MM.  
Pre-clinical safety 
 
ABT-199 was tested in a battery of safety pha rmacology assays and produced no effects in 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
5 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 central nervous system (CNS)/neur obehavioral, or respi[INVESTIGATOR_403404] 
600 mg/kg. In dogs, mild reductions in cardiac contra ctility and cardiac output were observed at 
plasma concentrations of ≥ 16 μg/mL; concentrations greater th an the concentration of ABT-199 
in humans (3.39 μg/mL at the 900 mg dose). However, no effects on blood pressure, heart rate, 
or electrocardiogram (ECG) parameters were obse rved in dogs at a maximum drug concentration 
of 46 μg/mL. 
 
Pre-clinical pharmacokinetics 
 
ABT-199 exhibited moderate permeability in th e Caco-2 assay. In rats, ABT-199 was widely 
distributed into liver, kidneys, spleen, heart, lung s, small intestine, and white fat, but was poorly 
distributed in testes, brain, muscle, and bone. ABT-199 showed moderate in vitro metabolic 
stability in hepatic systems across species teste d, with the exception of dog hepatocytes, where 
stability was low to moderate. In rat, 14.3% of  the dose was recovered as parent drug after [ADDRESS_508804]-dose, while 76.9% of the dose was excret ed as metabolites in bile. Profiles in bile 
indicated that metabolism was the major clearance mechanism, while biliary excretion of parent drug played a secondary role in drug eliminati on. Biotransformation of [3H]ABT-199 proceeded 
via a combination of oxidation and conjugation.  ABT-199 was not a potent inhi bitor of the cytochrome P 450 enzymes CYP3A4, CYP1A2, 
CYP2B6, or CYP2D6 (50% inhi bition constant [IC50] > 30 μM), but was a weak inhibitor of 
CYP2C19 (IC50 = 23.9 μM), a moderate inhibitor of CYP2C8 (IC50 = 4.4 μM), and a potent 
inhibitor of CYP2C9 (IC50 = 0.37 μM). At concentrations of 1, 3, and 10 μM, ABT-199 did not 
induce CYP3A4 or CYP1A2 expression in vi tro. ABT-199 was metabolized by [CONTACT_097]3A4; thus, 
its exposure could be affected wh en potent inhibitors or inducers of CYP3A4 are coadministered. 
 
Pre-clinical toxicology 
 
The primary toxicities associated with ABT-199 administration included effects on the 
hematologic system (decreased lymphocytes a nd erythrocytes) in mice and dogs; the male dog 
reproductive system (testicular germ cell depletion) ; and embryofetal toxicity in mice. In mice 
and dogs, ABT-[ADDRESS_508805] decreases in ly mphocytes in the peripheral blood (up to 
75% in mice and up to 80% in dogs) and in lymphoi d tissues. These findings are consistent with 
the expected pharmacologic effects of selectiv e Bcl-2 inhibition. In dogs, the recovery of 
lymphocyte counts (total lymphocytes, CD4+ and CD8+ T cells and mature B cells) was prolonged, requiring up to [ADDRESS_508806] sensitive lymphocyte subtype based on the ma gnitude of decrease and/ or the length of time 
required for recovery. ABT-199 e ffects on red blood cell mass parameters principally consisted 
of dose-related decreases in hematocrit and he moglobin in mice and dogs; these effects were 
adverse only at the highest dosag es in the 4-week mouse and dog st udies and were reversible. In 
dogs, ABT-199 produced adverse, non-reversible , non-dose-related microscopic findings of 
testicular germ cell depletion at all doses tested ; there were no testicular effects in mice.  
 Decreases of lymphocytes in lymphoid tissue were reversible in mice and re versible to partially 
reversible in dogs. ABT-[ADDRESS_508807] dosage 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
6 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 administered (150 mg/kg/day); the no-observed- adverse-effect level (NOAEL) was defined at 
the mid-dose of 50 mg/kg/day. ABT-199 was not tera togenic, and there we re no other effects on 
development or fertility. Other effects of ABT-199 included loss of hair pi[INVESTIGATOR_26608], 
single cell necrosis in various epi[INVESTIGATOR_403405] (e.g., gallbladder)  that was of minimal 
magnitude and produced no loss of mucosal integrit y, and increased pi[INVESTIGATOR_403406]. None of the effects were considered to be 
adverse, and all were reversible with the ex ception of hair coat discoloration. There was no 
evidence of in vitro or in vi vo genetic toxicity of ABT-199. 
 
Clinical experience with ABT-199 
 
Multiple ongoing Phase I/II [COMPANY_013], Inc. and Genentech/[COMPANY_002] clinical studies are evaluating safety, tolerability, pharmacokinetics, and efficacy of ABT-199 as monotherapy or in 
combination with other therapi[INVESTIGATOR_014] (rituximab, BR, bortezomib plus dexamethasone, or obinutuzumab) in subjects with hematologic malignancies. 
 
A drug-drug interaction (DDI) st udy evaluating the inte raction of ABT-199 a nd ketoconazole is 
ongoing. Additionally, a Phase 3 study of ABT- 199 plus rituximab compared with BR in 
subjects with CLL has been initiated.  Summary of Safety Data  
 
A total of 257 subjects were en rolled and had data available in  [COMPANY_013], Inc. studies as of 03 
February 2014. Of these 257 subjects, 150 subj ects had CLL/SLL, 82 subjects had NHL, 12 
subjects had MM, and 13 had AML. A total of  192 received the drug as monotherapy and 65 
received the drug in combination with other therapi[INVESTIGATOR_014]. Among the subjects who received ABT-
199, the median duration of drug administration was 126 days (range: 1 to 837 days), with 100 
subjects having received 180 days or longer of therapy. Additionally, 10 subjects were enrolled 
and had data available in Genentech/[COMPANY_002] oncology studies as of 03 February 2014. Eight 
subjects with CLL received ABT-199 + obinutuz umab in Study GP28331, and were on study for 
a median of 61 days (range: 3 to 195 days).  Two subjects received ABT-199 + BR in Study 
GO28440, and have been on study for 3 and 18 days, respectively.  
 Based on nonclinical and clinical data available with ABT-199 ad ministration the identified and 
potential risks are nausea, diar rhea, TLS, hematological effects (including neutropenia/febrile 
neutropenia, anemia, thrombocytopenia, a nd lymphopenia), serious and/or opportunistic 
infections, and decreased sper matogenesis. In addition, as ABT-199 is being evaluated in 
subjects with relapsed/refractory disease and has potential immunomodul atory properties, the 
risks of RS and secondary primary malignancies are closely monitored. 
 Clinical Pharmacokinetic and Pharmacodynamic Data  
 
Preliminary pharmacokinetic data with ABT- 199 are available from ongoing oncology Studies 
M12-175, M12-630, M13-365, and M13-367, and GP28331  in subjects with hematologic 
malignancies, and the ongoing immunology stud y in subjects with SLE (Study M13-093). 
The ABT-199 formulation currently us ed in clinical studies is a ta blet formulation with strengths 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
7 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 of 10, 50, and 100 mg. The tablet formulation was or ally administered after a low-fat meal. Food 
increased the bioavailability of  ABT-199 by 3- to 4-fold. Preliminary pharmacokinetic results 
indicated that the ab sorption of ABT-199 afte r the oral dosing was relatively slow. ABT-199 
plasma concentrations peaked at approxima tely 6 hours after dosing. The mean harmonic 
terminal phase elimination half -life of ABT-199 was approximate ly 17 hours and the mean oral 
clearance was approximately 13 L/hr after a si ngle dose. Preliminary data did not suggest 
apparent pharmacokinetics differences among subjects with CLL/small lymphocytic leukemia 
(SLL), NHL, multiple myeloma (MM), or SLE. The combined data from subjects with CLL/SLL 
and NHL suggested that ABT- [ADDRESS_508808] on ABT-199 pharmacokinetic s. On the basis of limited preliminary data 
from Cohort 1 of Study GP28331 (ABT-199 admini stered alone and in combination with 
obinutuzumab), obinutuzumab did not a ppear to affect ABT-199 exposure. 
 Clinical Efficacy as monotherapy 
 
Data from a phase I study in patients with rela psed/refractory CLL has been recently presented at 
the 2014 ASCO Annual Meeting (Seymour 2014). The data cut-off date was December 4, 2014. 
From the 84 patients in the study, 23 (27%) ha d del(17p) and 48 (57%) were refractory to 
fludarabine. The ORR was 79% with a CR/CRi rate  of 22% with a median DOR of 21 months. 
At 12 months, 91% of patients in CR and 65% in  PR remained progression free. The ORR was 
78% in del(17p) patients and 79% in fludara bine-refractory. The most common AEs were 
diarrhea (37%), nausea (36%),  neutropenia (35%) and anemia (8%). TLS was seen in 8%, 
including one grade 5 AE. Febrile neutrope nia, thrombocytopenia, hyperglycemia and 
hypokalemia were seen in 6% of patients each.  Also, results from a phase I st udy in patients with relapsed/r efractory NHL were presented 
(Davids 2014). So far, [ADDRESS_508809] been en rolled, 15 (35%) with MCL,  11 (26%) with FL, 10 
(23%) with DLBCL, 4 (9%) with WM, 2 (5%) w ith MZL, 1 (2%) with PMBCL, and 1 (2%) with 
MM. The ORR was 48%, 9/12 MCL (1 CR), 3/11 FL, 3/9 DLBCL (1 CR), 3/4 WM (1 CR), 1/2 
MZL, 0/1 PMBCL, and 0/1 MM. All the response s in DLBCL and FL patients were seen at 
doses >[ADDRESS_508810] common AEs were na usea (34%), URI (27%),  diarrhea (25%) and 
fatigue (21%). Also, Grade 3 or 4 seen we re anemia (14%), neutropenia (11%) and 
thrombocytopenia (9%). Laboratory TLS was seen in  1 patients with MCL and 1 patients with 
DLBCL.  2.3 
Rationale 
 
Overexpression of Bcl-2 in WM. The B-cell lymphoma-2 (BCL-2) fa mily of proteins is central 
to the regulation of apoptosis. Altered responses to normal apopt otic signals are one of the 
hallmarks of cancer and they are connected to def ects in the apoptotic machinery in cancer cells. 
Apoptosis occurs via activation of two different  pathways, the extrinsic pathway, triggered by 
[CONTACT_403450], and the intrinsic pathway, followed by [CONTACT_403451]. Studies have s hown that the intrinsic pathway 
is tightly controlled by [CONTACT_403452]- a nd anti-apoptotic BCL-2 family 
proteins (Bajwa 2012). Twenty -five known members of the BCL-2 protein family can be 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
8 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 grouped functionally according to th eir pro- and anti-apoptotic eff ects, as well as structurally 
according to the BCL-2 homology (BH) regions they contain. The six known anti-apoptotic 
family members, BCL-2, Bcl-x L, Mcl-1, Bcl-w, Bcl-b and A1, contain four BH domains (BH1-4) 
and a transmembrane domain (TM). Pro-apoptotic proteins are subdivide d into two classes: 
multi-domain members, such as Bax, Bak and Bok, which contain and share homology in the 
BH1, BH2, BH3 and BH4 domains and BH3-only pr oteins, including Bad, Bim, Puma, Bid, Bik, 
Noxa, Hrk and Bmf, which show homology only in the BH3 domain.  By [CONTACT_253893], we investigated di fferences in transcriptio nal regulation of CD19 
and CD138 selected cells representing the B-ce ll and plasma cell compartments, respectively, 
versus similar healthy donor derived bone marrow cells. Samples from 30 untreated WM patients 
were compared to those of 10 healthy donors (H atjiharissi 2007). These studies demonstrated 
that Bcl-2 was overexpressed in both B-cell and plasma cell compartments in WM patients in 
comparison to healthy donors. By [CONTACT_403453], the overexp ression of Bcl-2 protein 
has also been confirmed in a Spanish study on 60 cases meeting pathologic criteria for WM (San 
Miguel 2003). Enhanced Bcl-2 expression has also been linked to familial predisposition to WM in an Icelandic study (Ogmundsdotti r 2009), while use of Bcl-[ADDRESS_508811] shown preclinical 
(oblimersen, AT-101) as well as clinical activity (oblimersen) in WM (Gertz 2005; Paulus 2014).  
Previous BCL-2 inhibitors (ABT-263), although active in CLL and NHL, caused dose-dependent 
thrombocytopenia that limited further clinical de velopment. To circumvent this challenge, a 
unique BCL-2–small molecule cocrystal structur e was used to design ABT-199, a first-in-class 
BCL-2–selective inhibitor that causes substantially less platelet killing ex vivo and in vivo as 
compared to ABT-263. In addition to showing preclinical efficacy in BCL-2–dependent cell 
lines and tumor xenograft models, ABT-199 demonstr ated immediate activity in patients with 
refractory lymphoid malignancies wh ile causing only minor change s in platelet counts (Souers 
2013).   Preclinical evidence of ABT-199 activity in WM cell lines. In our laboratory, we evaluated the 
pro-apoptotic effects of ABT- 199 using Annexin V BCWM.1 and MWCL-1 (unpublished data). 
The treatment effects were evaluated followi ng 18 hours of culture with ABT-199 or the BTK 
inhibitor ibrutinib at 5 uM. As a reference, ibru tinib has been shown to be highly effective in 
patients with relapsed/refractory WM, showing an ORR of over 80%. We observed that ABT-
199 was able to induce a higher level of apoptosis th an ibrutinib in both cells lines (see figures). 
Interestingly, ABT-[ADDRESS_508812] conducted similar 
apoptotic essays using ABT-199, ibrutinib and the phosphatidylinositol 3-kinase inhibitor 
idelalisib in primary cells fr om WM patients (unpublished data ). We observed that ABT-199 at 
concentrations of 0.2 uM and 1 uM induced significantly higher leve ls of apoptosis than ibrutinib 
and idelalisib at concentrations of 1 uM. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
9 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508813] of ABT-199, ib rutinib and idelalisib 
at concentrations of 0.5 uM and 1 uM. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
10 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 
 
Clinical evidence of ABT-199 activity in WM patients. Davids and colleagues presented 
updated results from a phase I study using ABT-199 in patients with re lapsed/refractory NHL 
[25]. From the 4 patients with  WM enrolled, 3 responded for an ORR of 75%, including 1 
VGPR.  Hypothesis  Single agent ABT-199 (GDC-199) is safe and is asso ciated with a high over all response rate in 
patients with relapsed/refractory WM.  
2.4 
Correlative Studies Background 
 
MYD88 L265P is a recently identified somatic mutati on present in >90% of WM patients but in <5% 
of patients with other related processes such as CLL or MZL with plasmacytic differentiation or IgM 
myeloma (Treon 2012). Many groups have now validated the presence of this somatic mutation in WM patients. MYD88 L265P supports growth and survival of WM cells through both IRAK1 and 
IRAK4 (Treon 2012) as well as by [CONTACT_403454] (BTK) (Yang 2013). Based 
on these findings, we conducted a clinical trial us ing the BTK inhibitor ibrutinib in 63 patients with 
relapsed/refractory WM (Treon 2013). In this study, ibrutinib showed to be safe and effective. 
Median hemoglobin improved from 10.5 g/dl to 12.6 g/dl and IgM decreased from 3610 mg/dl to 1340 mg/dl. Bone marrow involvement decreased from 70% to 45% with a best ORR of 81% and a 
major response rate of 57%. The major response rate was 77% for patients with wild-type CXCR4 
vs. 30% in those with WHIM-like CXCR4 mutations. Decreases in serum IgM as well as 
improvements in hemoglobin were greater in patients with wild-type CXCR4.
 
In recent studies, the MYD88 and CXCR4 mutati onal status are predictiv e of clinical status, 
response to therapy and survival outcome s (Cao 2013, Treon 2013, Treon 2014). Activating 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
11 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508814] meet the following criteria  on screening examination to be eligible to 
participate in the study:  3.1.1 
Clinicopathological diagnosis of Waldenstrom’s Macroglobulinemia and meeting criteria for treatment 
using consensus panel criteria from the Second International Workshop on Waldenstrom’s 
macroglobulinemia (Owen 2003; Kyle 2003).   
   
3.1.2 Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of 
> [ADDRESS_508815] one prior therapy for WM.  
  
3.1.4  Age ≥ 18 years. 
 
3.1.5 ECOG performance status <2 (see Appendix A). 
  
3.1.[ADDRESS_508816] normal organ and marrow function as defined below: 
 Absolute neutroph il count > 1,000/mm3 
 Platelets > 50,000/mm3 
 Hemoglobin > 8 g/dL 
 Total bilirubin ≤ 1.[ADDRESS_508817]  
 AST (SGOT) and ALT (SGPT)  < 2.5X the institutional upper limit of normal 
 Creatinine clearance ≥50 ml/min 
 
3.1.7 Not on any active therapy for other malignancies with the exception of topi[INVESTIGATOR_403407].  
 
3.1.8 Females of childbearing potential (FCBP) must ag ree to use two reliable forms of contraception 
simultaneously or have or will have  complete ab stinence from heterosexual intercourse during the 
following time periods related to this study:  1) while participating in the study; and 2) for at least [ADDRESS_508818] be referred to a qualified provider of 
contraceptive methods if needed.  
   
3.1.9 Able to adhere to the study visit schedule and other protocol requirements. 
 
3.1.10  Ability to understand and the willingness to si gn a written informed consent document. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
12 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 3.2 Exclusion Criteria 
 
Participants who exhibit any of the following cond itions at screening will  not be eligible for 
admission into the study: 
3.2.1 Any serious medical condition, laboratory abnormality , uncontrolled intercurrent illness, or psychiatric 
illness/social condition that would prevent the participant from signing the informed consent form. 
 
3.2.[ADDRESS_508819] dose of study drug. 
 
3.2.4 Prior exposure to ABT-199 or BCL2 inhibitors. 
 
3.2.5 Prior or ongoing clinically signifi cant illness, medical condition, surgi cal history, physical finding, ECG 
finding, or laboratory abnormality that, in the investig ator's opi[INVESTIGATOR_1649], could affect the safety of the patient, 
including symptomatic hyperviscosity; alter the absorption, distribution, metabolism or excretion of ABT-
199; or impair the asse ssment of study results. 
 
3.2.6 Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy.  
 
3.2.7 Known CNS lymphoma.  
 
3.2.8 Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart 
failure, or myocardial infarction within 6 months of screening.  
 
3.2.9 [LOCATION_001] Heart Association classi fication III or IV heart failure.  
 
3.2.10  Malabsorption syndrome, disease significantly affectin g gastrointestinal function, or resection of the 
stomach or small bowel, ulcerative colitis, symptomatic  inflammatory bowel disease, or partial or 
complete bowel obstruction.  
 
3.2.11  Known history of Human Immunodeficiency Virus (HIV), chronic hepatitis B virus (HBV), or hepatitis 
C (HCV) requiring treatment.  Note:  Subjects with se rologic evidence of prior vaccination to HBV (i.e., 
HBs Ag-, anti-HBs+ and anti-HBc-) and positi ve anti-HBc from IVIG may participate  
 
3.2.12  Lactating or pregnant women. 
 
3.2.13  Inability to swallow tablets. 
 
3.2.14  History of non-compliance to medical regimens. 
 
3.2.15  Unwilling or unable to comply with the protocol. 
 
3.3 Inclusion of Women and Minorities 
 
Both men and women of all races and ethni c groups are eligible for this trial. 
4. REGISTRATION PROCEDURES 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
13 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 4.1 General Guidelines for DF/HCC Institutions 
 
Institutions will register eligible participants in  the Clinical Trials Management System (CTMS) 
OnCore. Registrations must occur prior to the initiation of protoc ol therapy. Any participant not 
registered to the protocol before protocol ther apy begins will be cons idered ineligible and 
registration will be denied.  An investigator will confirm eligibility criteria  and a member of the study team will complete the 
protocol-specific elig ibility checklist. 
 Following registration, participants may begin protocol therapy. Issu es that would cause 
treatment delays should be discussed with the Over all Principal Inve stigator (PI). If  a participant 
does not receive protocol thera py following registration, the part icipant’s registration on the 
study must be canceled. Registration cancellations must  be made in OnCore as soon as possible.  
 4.2 
Registration Process for DF/HCC Institutions 
 
DF/HCC Standard Operating Procedure for Human Subject Research Titled Subject Protocol 
Registration (SOP #: REGIST-101) must be followed.   
 
4.[ADDRESS_508820] Manager Kirsten Meid at [PHONE_8344] to 
verify dose level availabilities.   
 Following registration, participants  should begin protocol therapy within 5 days. Issues that 
would cause treatment delays shou ld be discussed with the Overal l PI.  If a participant does not 
receive protocol therapy followi ng registration, the participant’s registration on the study must be 
canceled.  The Project Manager should be notified of cancella tions as soon as possible. 
 4.4 
Registration Process for Other Investigative Sites 
To register a participant, the following documents  should be completed by [CONTACT_403455] [[PHONE_8345]] or e-ma iled [[EMAIL_7713]] to the 
Project Manager: 
 Copy of serum protein electropheresis, CBC, COMP, CT C/A/P, bone marrow biopsy 
 Screening visit note 
 Signed participant consent form 
 HIPAA authorization form 
 Eligibility Checklist 
 
The Eligibility Checklist should be filled out by a clinical  study staff member and the 
“Screening Staff” section must be signed by [CONTACT_29857].  Study staff at th e Coordinating Center 
will review the eligibility documentation and sign as th e “Enrollment Monitor.” 
The research nurse or data manager at the participating site will then call [[PHONE_8344]  or e-
mail [[EMAIL_7713]]  the Project Manager to verify eligibility.  To complete the 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
14 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 registration process, the Coordinator will fo llow DF/HCC Standard Operating Procedure for 
Human Subject Research Titled Subject Protocol  Registration (SOP #: REGIST-101B) and 
register the participant on the protocol.  The coordinator will fax or e- mail the participant study 
number, and if applicable the dose treatment level, to the particip ating site.  The coordinator will 
also call the research nurse or data manager at  the participating site and verbally confirm 
registration 
 5. 
TREATMENT PLAN 
 
Treatment will be administered on an outpatient ba sis. No investigational or commercial agents 
or therapi[INVESTIGATOR_403408]’s malignancy.    5.1 
Treatment Regimen 
 
ABT199  will be administered daily, with 28 consecutive days defined as a treatment cycle for 
cycles 2-26 for a maximum for 25 cycles once the target dose is reached. Treatment will be administered on an outpatient basis, except as specified below.  Repor ted adverse events and 
potential risks are described in  Section 7.  Appropriate dose m odifications are described in 
Section 6.  No investigational or commercial agents or therap ies other than those described 
below may be administered with the inte nt to treat the participant's malignancy. 
 5.[ADDRESS_508821] meet the followi ng criteria on Day 1 of cycles wi th clinic visits (i.e. 1, 2, 3, 6, 
9, etc.): 
 No grade 3 or 4 nausea, vomiting, or diarrhea (if persistent despi[INVESTIGATOR_403409]/or antidiarrheal thearpy) 
 No grade 4 or unmanageable nonhematologic grade 3 toxicities 
 Neutrophil count >/=500/ mm3 (growth factor permitted) 
 In subjects without base line thrombocytopenia:  
o Platelet count >/= 50,000/ mm3 in the presence of bleeding 
o Platelet count >/= 25,000 mm3 without bleeding 
 In subjects with base line thrombocytopenia: 
o Platelet count decrease <75% or >/= 20,000/ mm3, whichever is higher without 
bleeding 
o Platelet count decrease <50% in the presence of bleeding 
 5.[ADDRESS_508822] for a minimum of 4 weeks (+ 2 days ) and may continue until patients reach the 
maximum target dose level for [ADDRESS_508823] six pati ents (Cohort 1), the lead-in phase will consist of ABT-199 (GDC-
199) administered at a dose of 200 mg (2 tablet s) PO once daily for 7 (+2) days, followed by 400 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
15 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 mg (4 tablets) PO once daily for 7 (+2) days, followed by 800 mg (8 tablets) PO once daily until 
disease progression, unacceptable toxicity, or for total drug study duration of 26 cycles (2 years), 
whichever comes first. If no evidence of TLS is s een in the first six patients, for the remaining 
patients (Cohort 2) the lead-in phase will consis t of ABT-199 (GDC-199) ad ministered at a dose 
of 400 mg (4 tablets) PO once daily for 7 (+2)  days followed by 800 mg (8 tablets) PO once 
daily until disease progression or unacceptable toxicity for total drug study duration of 26 cycles 
(2 years), whichever comes first. Dose reductions due to toxicity will be permitted on information seen in Table 6-1.  The study drug ABT-[ADDRESS_508824] dose of each dose escalation (C1D1, C1D8, and C1D15 for the first 
[ADDRESS_508825] 6) until a dose of 
[ADDRESS_508826] be returned to the 
site at the next schedu led visit; this must be documented in the study diary.  Furthermore, they 
will be instructed to call the PI [INVESTIGATOR_403410]. If the pi[INVESTIGATOR_403411], this 
should be noted on the patient di ary, but a replacement dose shoul d not be taken that day. All 
dosages prescribed and dispensed to the particip ant, and all dose changes during the study must 
be recorded.  One cycle of ABT-[ADDRESS_508827] ration for 4 weeks ± 1 week. Prescriptions for 
ABT-199 will be written for daily administration for 1 cycle for pa rticipants in cycles 1 and 2, 
and will be written for daily administration for 12  weeks ± [ADDRESS_508828] Cycle 1 extended due to 
difficulties reaching the maximum target dose during dose escalation, a new script may be 
written mid-cycle.  Drug accountability will be d one at each study visit; unused drug and diaries 
will be collected from the participant, unused dr ug will be counted and returned to the pharmacy 
to be destroyed. A new prescription for either one cycle or three cycles, as detailed above, will be filled by [CONTACT_2299], and they  will be given a new diary.   
 Medication labels will comply with US legal requi rements and be printed in English. The storage 
conditions for study drug will be described on the medication label.  Tumor Lysis Syndrome Prophylaxis (Refer to Appendix B for Recommendations for Initial 
Management of Electrolyte Abnormalities and Prevention of Tumor Lysis Syndrome (TLS & 
refer to Appendix C for Definiti on of Laboratory and Clinical TLS))  
First Dose of ABT-[ADDRESS_508829] dose of  ABT-199. TLS prophylaxis includes: 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
16 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  An oral agent to reduce the uric acid level (e.g., allopurinol) to be initiated at least [ADDRESS_508830] the lead-in period (Cycle 
1) based on the ongoing risk of TLS development.  Subjects allergic to allopurinol must 
use another uric acid reducer. 
 Oral hydration consisting of fl uid intake of [ADDRESS_508831]- dose for subjects who demonstrate any 
laboratory changes. 
 Patients who are unable to maintain such oral  hydration will receive IV hydration of 1 L 
in the outpatient setting on Day 1 in additi on to oral hydration. In subjects for whom 
volume overload is considered a significant risk, hospi[INVESTIGATOR_26596]. 
 Chemistry and hematology laboratory tests are to  be collected and sent to local laboratory 
within [ADDRESS_508832] be 
reviewed by [CONTACT_093]. The inves tigator's decision to proceed with ABT-199 
treatment initiation may be ba sed on these laboratory values. 
 Chemistry laboratory tests must be performe d by [CONTACT_403456] 0 hour (pre-
dose, within [ADDRESS_508833] ration), [ADDRESS_508834]-dose (+/-30 minutes), 
and [ADDRESS_508835] been reviewed by [CONTACT_093]. 
 Day [ADDRESS_508836]-dose ch emistry laboratory 
values are reviewed by [CONTACT_093]. 
 If no significant findings suggest ive of clinical or lab TLS occur within 24 hours, the 
same dose will be continued until Day 7 in the outpatient setting. 
 If any significant laboratory ch anges are observed within the first 24 hours af ter initiation 
of dosing, see Appendix B, (Recommendations for Initial Management of Electrolyte 
Abnormalities and Prevention of Tumor Lysi s Syndrome [TLS]) for procedures to 
follow. Additional laboratory assessments may be performed per inve stigator discretion. 
 All 24-hour post-dose laboratory assessments (C hemistry and Hematology) may be taken 
within a +/- [ADDRESS_508837] receive the following TLS prophylaxis 
measures prior to subsequent  dose increases of ABT-199: 
 
 Continue administration of an oral ur ic acid reducer as indicated above.  
 Oral hydration consisting of flui d intake of approximately 2 L/ day starting at least [ADDRESS_508838] 24 hours after the dose. In subjects 
who are unable to maintain such oral hydrati on, IV hydration with 1 L of 0.9% normal saline 
will be given in the outpatient setting on the day of dose escalation. In subjects for whom 
volume overload is considered a significant risk, hospi[INVESTIGATOR_26596]. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
17 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  For subjects who receive their subsequent dose escalations in the outpatient in clinic setting, 
Chemistry laboratory tests will be performed by  [CONTACT_403457] 0 hour 
(pre-dose, within 4 hours before ABT-199 admi nistration), [ADDRESS_508839]-dose (+/-30 minutes) 
and [ADDRESS_508840] dose administration. Hematology laboratory tests should be performed at 0 
hour (pre-dose, within [ADDRESS_508841] 
ABT-199 administration. 
 Subjects must remain at the hospi[INVESTIGATOR_307], or clin ic, until the 8-hour laboratory values have been 
reviewed by [CONTACT_093]. 
 Day [ADDRESS_508842]-dose ch emistry laboratory 
values are reviewed by [CONTACT_093]. 
 If no significant findings suggestiv e of clinical or lab TLS occu r within 24 hours, the same 
dose will be continued until Day 7 in the outpatient setting. Additional laboratory 
assessments may be performed per investigator discretion. 
 All 24-hour post-dose laboratory assessments (C hemistry and Hematology) may be taken 
within a +/- 1 hour window, if necessary. 
 For subjects who are hospi[INVESTIGATOR_403412], Chemistry and 
Hematology laboratory tests will  be collected and sent to local laboratories upon admission. 
Chemistry tests will be perfor med by [CONTACT_403456]  0 hour (pre-dose, within 4 
hours before ABT-199 administration), 4, 8, 12 (+/- 30 minutes) and 24 (+/- 1 hour) hours 
post dose. These laboratory values must be re viewed in real time by [CONTACT_093]. Pre-
dose laboratory values will be collected and used  as baseline to assess potential electrolyte 
abnormalities occurring post ABT-[ADDRESS_508843] leaving the hosp ital or receiving any additiona l doses of the study drug. 
 Chemistry and Hematology laboratory tests fo r all subjects treated  in the outpatient 
setting must be collected within [ADDRESS_508844] ered prior to dosing (see Appendix B; 
Recommendations for Initial Management of Electrolyte Abnormalities and Prevention of Tumor Lysis Syndrome [TLS]).  
5.4 
General Concomitant Medication and Supportive Care Guidelines 
 
Participants will be instructed not to take a ny additional medications (including over-the-counter 
products) during the course of the study without prior consulta tion with the investigator. At each 
visit, the investigator will ask the participant about any new medications he/she is or has taken 
after the start of  the study drug. 
Anti-emetics are permitted if clinically indi cated. Standard supportive care medications are 
permitted. All Concomitant medications/S ignificant non-drug therapi[INVESTIGATOR_32546] ≤ 30 days prior to 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
18 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 start and after start of study drug, including physical therapy a nd blood transfusions, should be 
recorded. The following restrictions apply during the entire duration of the study: 
 No other investigational therapy should be given to participants. 
 No anticancer agents other than the study medi cation should be given to participants. If 
such agents are required for a patient then th e patient must first be withdrawn from the 
study. 
 Growth factors (i.e. G-CSF, GM-CSF, erythr opoietin, platelets grow th factors etc.) can 
be administered prophylactically, except to eligibility, and may be prescribed at the 
discretion of the treating physician for tr eatment-related hematologic events in 
accordance with ASCO guidelines, and to meet re-treatment criteria. 
 Transfusions (red blood cells, plat elets) can be administered to meet eligibility and for 
treatment-related hematologic events in acco rdance with ASCO guidelines, and to meet 
re-treatment criteria. 
 Concurrent administration of ABT-199 and mode rate or strong CYP3A4 inhibitors (such 
as clarithromycin, ketoconazole, itracon azole, and ritonavir) and inducers (such as 
rifampin and rifabutin) should be avoided. Alte rnatives should be sought if possible.  
During the ramp-up phase, moderate or st rong CYP3A4 inhibitors and inducers are 
prohibited. 
o If subjects require use of moderate or strong CYP3A inhibitors after the ramp-up 
phase, use with caution and reduce the venetoclax dose by 50% for moderate 
inhibitors and at le ast 75% for strong inhibitors du ring co-administration.  After 
discontinuation of CYP3A i nhibitor, wait for 2 to 3 days before increasing 
venetoclax dose back to maintenance/target dose. 
o If subject requires use of moderate or strong CYP3A inducers after the ramp-up 
phase and provided there is no alternative treatment available, the Principal Investigator [CONTACT_110594], and tr eatment should be administered with 
caution; patients should be closely monito red for potential lack of efficacy.  
Examples of moderate and strong CYP3A inhib itors and inducers are provided in Table 5-1.  
 If venetoclax is co-administered with warf arin, the international normalized ratio (INR) 
should be monitored closely. 
 Grapefruit and grapefruit juice affect CY P450 and P-glycoprotein activity and should 
therefore be avoided. 
 In addition, patients should avoid Seville orange s and star fruit, as well as the juice of 
these fruits, which are potent CYP3A4-inhibitors. 
 No green tea or foods/supplements containing green tea or extract. 
 No chronic treatment with systemic steroids  (at dosages equivalent to prednisone >20 
mg/day) or other immunosuppres sive agents. Topi[INVESTIGATOR_403413].  
Inhibitors of CYP3A4 are defined as follo ws. Examples of moderate and strong CYP3A 
inhibitors and inducers are pr ovided in Table 5-1.The genera l categorization into strong, 
moderate, and weak inhibitors accordi ng to the website is  displayed below: 
 A strong inhibitor is one that causes a >5-f old increase in plasma AUC values or >80% 
decrease in clearance. Strong inhibito rs are capi[INVESTIGATOR_403414].  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
19 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  A moderate inhibitor is one that  causes a >2-fold increase in plasma AUC values or 50-80% 
decrease in clearance. 
 A weak inhibitor is one that causes a >1.25-fold  but <2-fold increase in  plasma AUC values 
or 20-50% decrease in clearance.  
Table 5-1 Moderate and Strong Inhi bitors and Inducers of CYP3A4/5 
 
Inhibitors of CYP3A4/5 Inducers of CYP3A4/5 
Strong inhibitors:  
Boceprevir 
Clarithromycin Cobicistat Conivaptan Danoprevir/ritonavir Elvitegravir/ritonavir Idelalisib Indinavir Itraconazole Ketoconazole Mibefradil Lopi[INVESTIGATOR_054]/ritonavir Nefazodone Nelfinavir Ritonavir 
Paritaprevir/ritonavir combinations 
Posaconazle Squinavir Telaprevir Telithromycin Tipranavir/ritonavir Voriconazole Strong CYP3A inducers: 
Avasimibe 
Carbamazepi[INVESTIGATOR_403415]. John’s wort  Moderate CYP3A inducers: 
Bosentan Efavirenz Etravirine Modafinil Nafcillin 
Moderate inhibitors:  
Amprenavir 
Aprepi[INVESTIGATOR_403416]/ritonavir Diltiazem Erythromycin Fluconazole Fosamprenavir Imatinib  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
20 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508845], see the following link: 
http://www.fda.gov/Drugs/DevelopmentA pprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm080499.h
tm   
In addition to the medications listed in this table, subj ects receiving venetoclax should not consume grapefruit, 
grapefruit products, Seville oran ges (includin g marmalade containin g Seville oran ges) or Star fruits.
 
5.5 Criteria for Taking a Partic ipant Off Protocol Therapy 
 
Duration of therapy will depend on individual re sponse, evidence of disease progression and 
tolerance. In the absence of one of the above , treatment may continue for total drug study 
duration of 26 cycles (2 years), 25 cycles at the target dose, or unt il one of the following criteria 
applies:  
 Confirmed disease progression or development of new signs or symptoms of disease;  
 Development of symptomatic hyperviscosity 
 Lack of response to signs or symptoms that  prompted therapy afte r 12 weeks of therapy 
(defined as non-responder); 
 Commencement of new anti-neoplastic thera py (including radiation therapy) for WM or 
other malignancy including myelodysplasia  or WM disease transformation; 
 Intercurrent illness or hold of study dr ug for any other reason for >28 days;  
 Unacceptable adverse event(s); 
 In the study team’s opi[INVESTIGATOR_1649], participant has dem onstrated an inability or unwillingness to 
comply with the oral medication regi men and/or documentation requirements; 
 Participant decides to wi thdraw from the study; 
 General or specific changes in the participant's condition render the participant 
unacceptable for further treatment in th e opi[INVESTIGATOR_80021]. 
 Special mentions: 
 For participants meeting criteria for disease progression (based on consensus panel criteria for IgM 
response) but are deemed by [CONTACT_403458] T-199, these 
individuals will be permitted to co ntinue on protocol therapy at  the principal investigator’s 
discretion. Documentation describi ng the rationale for continuing be nefit shall be entered into the 
medical record. Clinical benefit will be determined by [CONTACT_403459], such as overall 
participant performance and disposition, complete blood counts, and when necessary, results from 
bone marrow biopsies and/or CT scans. In such  instances, any new nadir that may result with 
continued therapy will be used as the study nadir point for this patient. Patients must be on  >2 
consecutive weeks of therapy for determination of  a reliable IgM reading fo r response assessment 
purposes.  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
21 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508846] be 
documented in the case report form (CRF). Altern ative care options will be discussed with the 
participant. For Decentralized Subject Registrations, the Coordi nating Center study staff updates 
the relevant Off Treatment/Off St udy information in OnCore.  
In the event of unusual or life- threatening complications, treati ng investigators must immediately 
notify the Overall PI,  Jorge J. Castillo at [PHONE_8346] . 
 5.[ADDRESS_508847] be doc umented in the study-specific case report form 
(CRF). Alternative care options will be discussed with the participant. In the event of unusual or life-threatening complications, participating investigators must immediately notify the 
Principal Investigator, Jorge J. Castillo, MD, at [PHONE_8346].  The reason for taking a participant off study, and th e date the participant was removed, must be 
documented in the case report form (CRF).  For Decentralized Subject Registrations, the research team update s the relevant Off 
Treatment/Off Study information in OnCore.   
6. 
DOSING DELAYS/DOSE MODIFICATIONS 
 
Dose delays and modifications will be made as indicated in the following table(s). The 
descriptions and grading scal es found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 will be uti lized for dose delays and dose modifications. A 
copy of the CTCAE version 4.0 can be downloaded from the CTEP website  http://ctep.cancer.gov/proto colDevelopment/electroni c_applications/ctc.htm .  
 
If possible, symptoms should be managed sympto matically. In the case of  toxicity, appropriate 
medical treatment should be used (including anti -emetics, anti-diarrheals , etc.). All adverse 
events experienced by [CONTACT_403460], through the study and until the final st udy visit. Participants continuing to experience 
toxicity at the off study visit may be contact[CONTACT_403461].  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
22 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508848] be interr upted because of unacceptable 
toxicity, drug dosing will be interrupted or modi fied according to rules described in Table 6-1.  
 If dose reductions of ABT-199 are needed dur ing the lead-in period, dose escalation should 
continue on a weekly basis to r each the targeted dose of 800 mg PO daily (e.g. if a participant 
cannot tolerate the 400mg dose escalation, they should be redu ced back to 200mg for 1 week, 
and then re-challenged at 400mg the following wee k, etc). In this case, the lead-in period could 
last for >[ADDRESS_508849] 
dose 
escalation 400mg 200mg 100mg - - 
Week 3+ 
Escalation to 
target dose 
and all cycles 
therafter 800mg 600mg 400mg 200mg 100mg 
 
 Table 6-[ADDRESS_508850] Lead-in 
Phase ABT-199 dosin
g ABT-199 
Dose 
level 1 Dose 
level     
-1Dose level -
2 Dose level 
-3 Dose Level   
-4 
Week 1 
starting dose 400mg 200mg 100mg - - 
Week 2+ 
Escalation to 
target dose 
and all cycles 
therafter 800mg 600mg 400mg 200mg 100mg 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
23 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Dosing will be held for any of the following conditions: 
 Grade 4 ANC (<500/ μL) for >7 days (neutrophil growth factors are permitted). 
 Grade 4 Platelets (<25,000/ μL) or in subjects with baseline  thrombocytopenia, decrease of > 
75% from baseline or <20,000/ μL, whichever is higher. Hold until grade 3 unless active 
bleeding. 
 Grade 3 or 4 nausea, vomiting, or diarrhea (if persistent despi[INVESTIGATOR_403417]/or 
antidiarrheal therapy). 
 Any other related grade 4 t oxicities and any unmanageable  non-hematologic Grade 3 
toxicities. 
 Drug Modification/Discontinuation Actions for ABT-199-related events 
 
 1st Hold: ABT-199 until recovery from criteria to hold; may rest art at original dose level. 
 2nd Hold: ABT-199 until recovery from criteri a to hold; restart at -1 dose level. 
 3rd Hold: ABT-199 until recovery from criteria to hold; restart at -2 dose level (if applicable, 
see tables 6-1 and 6-2) 
 4th Hold: ABT-199 until recovery from criteria to hold; restart at -3 dose level (if applicable, 
see tables 6-1 and 6-2) 
 5th Hold: ABT-199 until recovery from criteria to hold; restart at -4 dose level (if applicable, 
see tables 6-1 and 6-2 
 6th Hold: Discontinue ABT-199 
 
If a participant has a drug hold, the schedule of assessments will not change.  If participants do not meet treatment criteria on Day 1 of th e cycle, the cycle will not be delayed.  
  
7. 
ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of reported and/or  potential AEs (Section 7.1) a nd the characteristics of an 
observed AE (Section 7.2) will determine wh ether the event requires expedited reporting in 
addition  to routine reporting.  
 7.[ADDRESS_508851]  
 
[IP_ADDRESS]  Adverse Event List(s) for ABT199  
 
Most subjects (89.6%) reported at  least [ADDRESS_508852] common adverse events were 
nausea (31.3%), diarrhea (29.2%),  neutropenia (25.5%), fatigue (22.9%), and upper respi[INVESTIGATOR_19629] (22.4%). A summary of the treatment-emergent adve rse events reported in > 10% 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
24 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 subjects treated with ABT-199 monotherapy, and relationship to  study drug, is presented in 
Table 7-1.  Table 7-1. Treatment-Emergent Adverse Events  in >10% of Subjects Treated with ABT-
199 Monotherapy and Relationship to Study Drug 
 
 
 
A summary of adverse events NCI CTCAE grade 3 and above reported in more than 1% of the 
subjects treated with ABT-[ADDRESS_508853] common adverse events gr ade 3 and above were neutropenia (21.9%) and 
anemia (12.0%).      
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
25 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Table 7-2. Treatment-Emergent Adverse Events  NCI CTCAE Grade 3 and Above in > 1% 
of the Subjects Treated with ABT-199 Monotherapy and Relationship to Study Drug  
 
 
A summary of serious adverse ev ents reported in more than 1% of the subjects treated with 
ABT-[ADDRESS_508854] 
common serious adverse event wa s febrile neutropenia (4.2%). 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
26 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Table 7-3. Treatment-Emergent Serious Adverse Events Reported in > 1% of the Subjects 
Treated with ABT-199 Monotherapy a nd Relationship to Study Drug 
 
 
 
Ten of 192 (5.2%) subjects treated with ABT-[ADDRESS_508855] common adverse even t that led to death was malignant neoplasm 
progression (4 subjects, 2.1%). All other adverse ev ents leading to death included small intestinal 
obstruction, multi-organ failure, sudden death (in the setting of TLS), pneumonia viral, mental 
status changes, and respi[INVESTIGATOR_403418] (0.5% each). No other deat hs were attribut ed to ABT-199. 
 Nineteen of 192 (9.9%) subjects treated with ABT-[ADDRESS_508856] udy drug discontinuation 
was malignant neoplasm progression (in 3 subjects, 1.6%). All other adverse events leading to 
discontinuation were reported  in [ADDRESS_508857] (0.5%) each.  
 
Tumor Lysis Syndrome 
 TLS is considered an adverse event of special interest (AESI).  There is a potential for TLS in subjects affected by [CONTACT_403462], especially in those 
with bulky disease, elevated pretreatment lactate dehydrogena se (LDH) levels, elevated 
leukocyte count, renal dy sfunction, and dehydration. The risk of  TLS in patients with WM is, 
however, extremely rare. In fact, no cases of TLS  have been described in WM patients in the 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
27 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 literature (PubMed search perfor med on 02/10/2015 without date or  language restriction using 
the keywords: “waldenstrom*” AND “tumor lysi s”), and we have not observed the occurrence 
TLS in our database, which includes approxima tely 1,500 patients with WM. For these reasons, 
we do not believe the risk stratification crit eria for TLS used for CLL, NHL and MM are 
applicable in WM patients. To err on the side of safety, we will take TLS precautionary measures 
in all patients enrolled  in the present study. 
 Based on nonclinical and clinical data available with ABT-199 ad ministration, the identified and 
potential risks, besides TLS ar e nausea, diarrhea, hematologica l effects (including lymphopenia, 
neutropenia/febrile neutropenia,  thrombocytopenia, and anemia),  serious and/or opportunistic 
infections, and decreased sper matogenesis. In addition, as ABT-199 is being evaluated in 
subjects with relapsed/refractory disease and has potential immunomodul atory properties, the 
risks of Richter's Syndrome and secondary  malignancies are closely monitored. 
 Hematological Effects  All hematological adverse events were identified via re view of events reported in the Blood and 
Lymphatic Disorders System Organ Class (SOC). In particular, events of neutropenia/febrile 
neutropenia, anemia/hemoglobin decreased, and thrombocytopenia are reviewed and 
summarized below. Lymphopenia and opportunis tic infections are discussed together. 
 Neutropenia/Febr ile Neutropenia 
 Neutropenia and febrile neutr openia are potential risks of  dosing with ABT-199 based on 
suspected Bcl-2 mechanism-based toxicity.   One of 192 subjects (0.5%) trea ted with ABT-199 monotherapy e xperienced a serious adverse 
event of neutropenia (considered related to AB T-199); no serious adverse events were reported 
in the combination therapy studies. None of the events of neutrope nia were considered serious or 
resulted in deaths or discontinuations.  In ABT-[ADDRESS_508858] s (4.2%) experienced serious adverse events 
of febrile neutropenia; these events were considered rela ted to ABT-199 treatment by [CONTACT_164509] 7 subjects (3.6%). One monot herapy subject (0.5%) discontinued the study due 
to an adverse event of febrile ne utropenia; there were no deaths due  to febrile neutropenia. In the 
combination Study M13-365, 1 of 38 subjects (2.6 %) experienced a seriou s adverse event of 
febrile neutropenia; this event was not cons idered related to ABT-199. Additionally, in the 
combination Study M12-630, 3 of 22 subjects (13. 6%) experienced serious adverse events of 
febrile neutropenia; 2 of these (9.1%) were considered related to ABT-199 treatment. There were 
no deaths or discontinuations due  to febrile neutropenia in an y combination therapy studies. 
 The events of neutropenia/febrile neutr openia were observed across all ABT-199 oncology 
studies; however, data are confounded by [CONTACT_403463][INVESTIGATOR_403419]. Furthermore, the higher percentage of these 
events in combination studies is confounded by [CONTACT_403464] (Study M12- 630) and rituximab (Study M13-365), both of 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
28 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 which are known to be associated w ith neutropenia/febrile neutropenia. 
 Based on clinical observations with the 1st gene ration Bcl-[ADDRESS_508859] received multiple  prior therapi[INVESTIGATOR_13265]/or have significant bone 
marrow involvement, may be at particular high ris k. If determined to be clinically indicated by 
[CONTACT_403465], G-CSF may be  administered during 
dosing of ABT-199. The use of G-CSF support is strongly recommended for subjects with Grade 
4 neutropenia (ANC <500/ μL). If the subject presents with  febrile neutropenia or Grade 4 
neutropenia for more than one week despi[INVESTIGATOR_403420] G-CSF support, ABT-199 dosing 
should be interrupted until ANC recovery to >500/ μL. ABT-[ADDRESS_508860] s not responding to G-CSF despi[INVESTIGATOR_386208]-199 
interruption should undergo furthe r evaluation to determine the etiology of the neutropenia. 
 Anemia  Only 1 of 192 subjects (0.5%) in  the monotherapy studies experien ced a serious adverse event of 
anemia; the event was considered  to have a reasonable possibili ty of being related to ABT-199. 
Although the percentage of all adve rse events of anemia was highe r in combination studies when 
compared to monotherapy, the data are conf ounded by [CONTACT_403466]. There were no serious adverse events of  anemia in any of the combination therapy 
studies. None of the events result ed in deaths or discontinuations. 
 Thrombocytopenia  Thrombocytopenia is a mechanism-based toxicity  of the first-genera tion Bcl-2/Bcl-XL dual 
inhibitor navitoclax (ABT-263). As a second-ge neration, Bcl-2-selective inhibitor, ABT-199 is 
not expected to exhibit this type of thrombocytopenia; neve rtheless, adverse events of 
thrombocytopenia remain of inte rest as data are collected. 
 In ABT-199 monotherapy studies, only 1 of 192 subjects (0.5%) experien ced a serious adverse 
event of thrombocytopenia; this  event was considered possibly related to ABT-199 (the subject 
was in the NHL arm of Study M12-175). One additional monotherapy subject (0.5%) discontinued the study due to a nonserious adve rse event of thrombocytopenia, which was 
considered probably related to ABT-199. There were  no deaths due to thrombocytopenia. In the 
combination therapy studies, there were no seri ous adverse events of thrombocytopenia, and no 
deaths or discontinuations due to thrombocytopenia. 
 Additionally, 4 subjects in monot herapy studies (2.1%) reported autoimmune thrombocytopenia; 
3 of which (1.6%) were both grade [ADDRESS_508861]  of selective Bcl-2 inhibition by [CONTACT_345040]-199, and 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
29 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508862]-Specific (Bcl-2 specific) 
Company MedDRA query (PMQ). In monotherapy studies, adverse events in 6 subjects (3.1%) 
were identified on the basis of this PMQ. Thes e included [ADDRESS_508863] with  an adverse event of 
nocardiosis (0.5%) and 5 s ubjects (2.6%) with events  of oral candidiasis. 
 There is a potential for clinical ly significant lymphopenia in this  study. If clinically indicated, 
anti-infective prophylaxis should be implemented at the investigator's  discretion, including 
appropriate prophylaxis for viral, fungal, bacterial or Pneumocystis infections. Potential for drug-
drug interactions should be considered. Most an ti-fungals are excluded and other commonly used 
agents may be cautionary or prohibited due to drug-drug interactions. Pl ease refer to Table 1, 
Table [ADDRESS_508864] s (11.5%) treated with ABT- [ADDRESS_508865] common serious adverse events 
for monotherapy were influenza and pneumonia (in 3 subjects, 1.6% each.) Of these, influenza 
was considered to have a reasonable possibili ty of being related to ABT-199 in 2 subjects 
(1.0%). One serious adverse event of pneumonia viral (0.5%) resulted in discontinuation of 
ABT-[ADDRESS_508866] death; this event occurr ed in the CLL arm of Study M12-175 at 400 mg 
ABT-199, and was considered not rela ted to ABT-199 by [CONTACT_093]. 
 Additionally, in the combination thera py Study M13-365, five of 38 subjects (13.2%) 
experienced serious adverse even ts (bronchitis bacterial, infl uenza, lung infection, pneumonia 
haemophilus, and rotavirus infection, in [ADDRESS_508867] each). Bronchitis bacterial, pneumonia 
haemophilus, and rotavirus infection were consider ed to have a reasonable  possibility of being 
related to ABT-199. And in the combination th erapy Study M12-630, [ADDRESS_508868] no reasonable possibility of being 
related to ABT-199. None of the adverse events in combination therapy studies resulted in 
discontinuation or death.  The types of infectious events observed were generally consistent  with those anticipated in the 
population of heavily pretreated CLL/NHL subjects.  Cardiac Function  As a result of findings of mild reductions in m yocardial contractility and cardiac output (but not 
blood pressure, heart rate, or ECG) observe d following ABT-199 administration in the 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
30 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 anesthetized cardiov ascular dog model at concentrations of ≥ 16 μg/mL (concentrations greater 
than the concentration of ABT-199 in humans [3.39 μg/mL at the 900 mg dose]). 
 Pre- and post-dose left ventricular ejection frac tion (LVEF) assessments (multi-gated acquisition 
scan/echocardiogram) were collected per pr otocol in monotherapy Study M12-175. As of 03 
February 2013, the mean baseline LVEF among 76 subjects for whom data were available is 
64.25 mmHg (SD: 6.72 mmHg; range: 43.00 to 8 0.00 mmHg). Pre- and post-dose ABT-199 
LVEF assessment is available for 14 subjects (all from Study M12-175). Of these [ADDRESS_508869] had a decrease in LVEF of more than  10%. Additionally, there were no subjects with 
LVEF less than 40 mmHg (grade [ADDRESS_508870]-dose).  Medical review of all events retrieved using the Cardiac Fail ure (narrow) SMQ identified no 
treatment-emergent serious or non-serious even ts of cardiac failure/left ventricular function 
decrease that were related to ABT-199 or resulte d in discontinuation or death. Events of edema 
peripheral were reported at a fr equency of 8% or lower in monotherapy studies and combination 
Studies M13-365 and M12-630. One event each ( 2.6%) of left ventri cular dysfunction and 
pulmonary edema was identified in Study M13-365;  both events were considered to have no 
reasonable possibility of being related to AB T -[ADDRESS_508871] medical history.  Thus, based on data to date, the Sponsor believes  that there is no risk  of decreased cardiac 
function/decrease in LVEF fo llowing ABT-199 administration. 
 Richter's Syndrome (RS) due  to disease progression 
 The reported incidence of RS (the clinical pathologic transfor mation to an aggressive lymphoma) 
in the published literature ranges from approximately 2% to 3% to as high as 16%, depending on 
the characteristics of the populati on studied. The evolution to RS typi[INVESTIGATOR_403421] a role in 
the minority of cases.  Disease progression due to RS was reported for a total of 18 of 160 subjects (11.3%) in the ABT-
199 oncology clinical program. (This included 14  of 95 subjects in Study M12-175, 3 of 38 in 
Study M13-365, 1 of 17 in Study M13-982, and zero  subjects in Genentech/[COMPANY_002] Studies 
GP28331 [N = 8] and GO28440 [N = 2] ). Sixteen of 18 subjects ( 88.9%) had prior exposure to 
fludarabine. The median number of prior treatmen t regimens was 4 (range: 1 to 9). The majority 
of subjects (11 of 18, 61.1%) were diagnosed with CLL more than 5 years before study 
enrollment, with 7 (38.9%) being diagnosed more than 10 years before study enrollment. At the 
time of the RS diagnosis, 9 of 18 subjects (50.0 %) were on study for less than [ADDRESS_508872] subjects (14 of 18, 77.8%) were on study for less than a year. Nine of 16 subjects (56.3%) 
with RS who were analyzed for 17p del status were positive for 17p del; this subject population 
was also heavily pretreated. The diagnoses we re [ADDRESS_508873] transformed to cl assic Hodgkin's Lymphoma. 
 The role of ABT-199 treatment in these cases is unclear. The frequency of RS cases observed to 
date in the ABT-199 oncology clini cal program in subjects with CLL (11.3%) is within the range 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
31 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508874] undergone prior chemothe rapy treatments. Additionally, due to the immunomodulatory 
mechanism of action of ABT-199, the risk of secondary malignancy cannot be ruled out. 
 A total of 5 treatment-emergent secondary ma lignancies were identified following medical 
review of events retrie ved using the SOC of neoplasms beni gn, malignant, and uns pecified of the 
Malignancies SMQ: bladder tr ansitional cell carcin oma recurrent, lung adenocarcinoma, 
esophageal adenocarcinoma, prostate cancer, squamous cell carcinoma, and squamous cell 
carcinoma of the lung in [ADDRESS_508875] (0.5%) eac h. None of these events in monotherapy and 
combination therapy studies were considered to ha ve a reasonable possibili ty of being related to 
ABT-199.  These events are consistent with that expect ed in an elderly popul ation with relapsed 
hematological malignancies and a hist ory of multiple prior therapi[INVESTIGATOR_014]. 
 7.2 
Adverse Event Characteristics 
 
 CTCAE term (AE description) and grade:  The descriptions and grading scales found 
in the revised NCI Common Terminology Criter ia for Adverse Events (CTCAE) version 
4.[ADDRESS_508876] access 
to a copy of the CTCAE version 4.0.  A copy of the CTCAE version 4.0 can be 
downloaded from the CTEP web site http://ctep.cancer.gov/proto colDevelopment/electroni c_applications/ctc.htm . 
 
 For expedited reporting purposes only:   
- AEs for the agent(s) that are listed above should be reported only if the adverse event 
varies in nature, intensity or  frequency from the expected toxicity information which 
is provided. 
- Other AEs for the protocol that do not requ ire expedited reporting are outlined in the 
next section (Expedited Adverse Event Repor ting) under the sub-heading of Protocol-
Specific Expedited Adverse Event Reporting Exclusions. 
 
 Attribution  of the AE: 
- Definite – The AE is clearly related  to the study treatment. 
- Probable – The AE is likely related to the study treatment. 
- Possible – The AE may be related  to the study treatment. 
- Unlikely – The AE is doubtfully related to the study treatment. 
- Unrelated – The AE is clearly NOT related  to the study treatment. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
32 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508877]  report to the Overall PI [INVESTIGATOR_403422] (SAE) that occurs 
after the initial dose of study tr eatment, during treatment, or within [ADDRESS_508878] 
dose of treatment on the local institutional SAE form.  
 7.3.2 For multi-institution studies where a DF/HCC in vestigator is serving as the Overall 
Principal Investigator, each participating institution must  abide by [CONTACT_98898]/HCC. This applies to any medical event equivalent to an 
unexpected grade 2 or 3 with a possible, pr obable or definite at tribution, all grade 4 
toxicities, and grade 5 (d eath) regardless of study phase or attribution. 
 
7.3.3 
DF/HCC Expedited Reporting Guidelines 
 
Investigative sites within DF/HCC will repor t AEs directly to the DFCI Office for 
Human Research Studies (OHRS) pe r the DFCI IRB reporting policy.  
 Other investigative sites will report AEs to their respectiv e IRB according to the local 
IRB’s policies and procedures in reporti ng adverse events. A copy of the submitted 
institutional AE form should be forwarded to the Overall PI [INVESTIGATOR_198016].    
 
 
 
Attribution DF/HCC Reportable AEs
Gr. 2 & 3 AE 
Expected Gr. 2 & 3 AE 
Unexpected Gr. 4 AE Expected Gr. 4 AE 
Unexpected Gr. 5 AE 
Expected or 
Unexpected
Unrelated 
Unlikely Not required Not required 5 calendar days# 5 calendar days 24 hours* 
Possible 
Probable 
Definite  
Not required  
5 calendar days  
5 calendar days#  
5 calendar days  
24 hours* 
# If listed in protocol as expected and not requiring ex pedited reporting, event does not need to be reported. 
 
* For participants enrolled and actively participating in the study or for AEs occurring within [ADDRESS_508879] 
intervention, the AE should be reported within  1 business day of learning of the event. 
 
 
The Overall PI [INVESTIGATOR_403423].  
 
7.3.4 Protocol-Specific Expedited Adve rse Event Reporting Exclusions 
 
For this protocol only, the AEs/grades listed below do not require expedited reporting to 
the Overall PI [INVESTIGATOR_52457].  However, they still must be reported through the routine 
reporting mechanism (i.e. case report form). 
 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
33 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 CTCAE SOC Adverse Event Grade Hospi[INVESTIGATOR_059]/ 
Prolongation of 
Hospi[INVESTIGATOR_403424] d [ADDRESS_508880] be reported to DFCI 
IRB and PI 
 
 7.4 
Expedited Reporting to the Food and Drug Administration (FDA) 
 
The Overall PI, as study sponsor, will be responsible for all co mmunications with the FDA. The 
Overall PI [INVESTIGATOR_57895], regardless of the site of occurrence, any serious adverse event 
that meets the FDA’s criteria for expedited reporting following the reporting requirements and 
timelines set by [CONTACT_1622].  7.5 
Expedited Reporting to Hospi[INVESTIGATOR_403425].  
 
7.6 Expedited Reporting to Abbvie Drug Safety Department 
Adverse Events; Pregnancy.  In addition to compliance with all FDA reporting requirements 
pursuant to 21 C.F.R. § 312, the Principal Investigator [INVESTIGATOR_67417]: 
a. report all serious adverse events experien ced by a study subject receiving an [COMPANY_013] 
product within [ADDRESS_508881].  Princi pal Investigator shall make av ailable to [COMPANY_013] promptly 
such records as may be necessary and pert inent to investigate any such event, if 
specifically requested by [CONTACT_403467]; and in addition; report all non-serious a dverse events 
of tumor lysis syndrome fo r studies involving ABT-199. 
i. Serious AE (SAE) means any untoward me dical occurrence that meets one of the 
following criteria: 
i. Results in death 
ii. Is life-threatening 
iii. Requires inpatient hospi[INVESTIGATOR_272] >24 hours or prolongation of 
hospi[INVESTIGATOR_403426]. Is a congenital anomaly 
v. Results in persistent or significant disability/incapacity 
vi. Other serious (Important Medical Events )  Events that do not fit the other 
outcomes but may require medical or su rgical intervention to prevent one 
of the other outcomes.   
b. copy [COMPANY_013] on the submission to the FDA of  events meeting the definition of IND 
safety reports at the time of submission to the Agency; and 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
34 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508882] ev ent during the course of pregnancy or upon 
delivery.   
[COMPANY_013]’s contact [CONTACT_403468] e drug experiences, pregnancy experiences, 
non-serious adverse events of tumor ly sis syndrome, and communication of FDA 
submissions of IND safety reports shall be  [EMAIL_1987]   
 
7.[ADDRESS_508883]  be reported in routine study data submissions to the Overall PI [INVESTIGATOR_52458].  AEs reported through expedited processes (e.g., reported to the 
IRB, FDA, etc.) must also be reporte d in routine study data submissions.  
8. PHARMACEUTICAL INFORMATION 
 
A list of the adverse events and potential risk s associated with the investigational agent 
administered in this study can be found in Section 7.1.  8.[ADDRESS_508884] 7O7S and a molecular weight of 868.44. ABT-
199 is a light yellow to dark yellow powder, and is freely soluble in vinylpyrrolidone dimer; 
soluble in polyethylene glycol  (PEG) 400; very slightly solu ble in 1% (w/v) Cremophor RH40, 
and is practically insoluble in water. There are no optical isomers. 
 
8.1.[ADDRESS_508885] not be opened and re-
packaged.  It will be packaged in high de nsity polyethylene (HDP E) plastic bottles to 
accommodate the study design.  Each bottle will be labeled per regulatory requirements.  Labels 
must remain affixed to the bottle.  8.1.[ADDRESS_508886] be stored at 15° to 25 °C (59° to 77°F). The investigational products 
are for investigational us e only and are to be used only within  the context of this study.  The 
study drug supplied for this study must be mainta ined under adequate security and stored under 
the conditions specified on the label.  8.1.[ADDRESS_508887] ug will be labeled and handled as open-label 
material, and packaging labels will fulfill all requirements specified by [CONTACT_20556]. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
35 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508888] meal of the day, at approximately the same 
time each day. ABT-199 should be administered w ith 8 ounces (approximately 240 mL) of water 
(avoid GRAPEFRUIT JUICE due to CYP3A4 inhi bition).  The tablets should be swallowed 
intact.  If a dose is missed, it can be taken up to  [ADDRESS_508889] be returned  to the site at the next scheduled visit.   
 
Dietary habits around the time of ABT-199 intake should be as c onsistent as possible throughout 
the study. If the pi[INVESTIGATOR_403427], but a replacement dose 
should not be taken that day. A study diary will be used to ai d with study drug administration 
compliance.   
 
Except for cycle 1 which may be longer, one cycl e of ABT-199 is once daily, oral administration 
for 4 weeks ± 1 week. At each study visit, e nough ABT-199 will be dispensed until the next 
cycle. For cycle 1, additional drug may be dispense d mid-cycle if necessary.  For visits occurring 
monthly (every 4 weeks ± 1 week), one cycle of  pi[INVESTIGATOR_3353] (5 weeks of ABT-199 therapy) will be 
dispensed. For visits occurring every 12 weeks ± 2 w eeks), three cycles of pi[INVESTIGATOR_3353] (14 weeks) will 
be dispensed. 
 
8.1.6 Ordering 
 
ABT-199 is an investigational agent and will be supplied fr ee-of-charge from [COMPANY_013] and 
Genentech/[COMPANY_002].  The contact [CONTACT_403469]: 
[EMAIL_7714] 
 
8.1.[ADDRESS_508890] 
Form (DARF) or another comparable drug accoun tability form.  (See the NCI Investigator’s 
Handbook for Procedures for Drug Accountability and Storage.) 
 
8.1.[ADDRESS_508891] Form. 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
36 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 9. BIOMARKER, CORRELATIVE , AND SPECIAL STUDIES 
 
9.1 Biomarker Studies 
 
9.1.1 Laboratory Correlative Studies 
 
Assessment of MYD88 L265P and CXCR4 WHIM genotypi[INVESTIGATOR_007]. 
 
An allele-specific polymerase-chain-reaction (PCR) assay will be used to detect MYD88L265P 
mutations. CXCR4WHIM mutation status will be determin ed by [CONTACT_403470], and 
allele-specific PCR will be used to detect CXCR4S338X C→G and C→A mutations in CD19-
selected bone marrow cells (Xu et al, 2013; Hunter et al,2014; Treon et al, 2014). For PCR 
assays two large lavender tops of bone marrow aspi[INVESTIGATOR_403428] d bone marrow biopsy. 
  
 
                            
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
37 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 10. STUDY CALENDAR 
STUDY CALENDAR 
 
  Screening
*  
 30 days 
from 
study entry Treatment Phase
7Off 
Treatment Assessment  Within 4 weeks of completion of or removal from study ± 2 weeks Follow-Up 
Phase
Cycles 1*(4 weeks +2 days), 2 (4 weeks +/- 1 
week) Cycles 3, 6, 
9, etc. until study completion (12 weeks ± 2 week) Post Treatment; 
Every 24 weeks ± 2 weeks for 2 years or until next therapy 
Physical exams1, vital 
signs (Temp, HR, RR, BP), weigh
t, heigh t X X X X X 
ECOG performance 
status (see Appendix A)X X X X X 
CT of the chest & 
abdomen / pelvis2 X  X2X2X (if applicable) 
Bone marrow biopsy 
and aspi[INVESTIGATOR_1516]3 X  X3 X X  (if applicable) 
Serum immuno-electropheresis X X X X 
X 
IgM  X***    
Complete Blood Count 
plus differential1,4 X X** X X X 
Coagulation profile: 
PT, PTT, PT-INR5 X     
Chemistry including: Electrolytes, Renal (BUN, Creatinine) and Hepatic function testing 
[ALT (SGPT), AST 
(SGOT), Alk phos, total Bilirubin], albumin, total protein X X** X X 
X 
Tumor lysis labs: 
Potassium, Creatinine, Bicarbonate, Calcium, 
Phosphorus, LDH, uric 
acid X X**   
 
Magnesium X X  
Beta-2 microglobulin, 
HIV, Von Willebrand X     
Pregnancy Tes t6 X  
HBsAg, HBsAb, 
HBcAB X     
HCV Ab X  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
38 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Response Assessment  X X X X 
Review patient diary   X X  
Adverse event 
monitoring (see section 6)  X X X 
X 
* Physical exam, vital signs, and weight do not need  to be repeated if Cy cle 1, Day [ADDRESS_508892] dose.  
 **TLS monitoring and management w ill depend on criteria in section 5.[ADDRESS_508893] six participants (cohort 1), 
and Cycle 1 Day 1 and 8 for all other participants (cohort 2). 
 *** IgM will be monitored weekly for the first 6 weeks of study treatment for all participants 
(i.e. Days 1,8, 15, 22, 29, and 36 +/- 2 days) to  evaluate the potential for IgM flare. 
 
1More frequent visits may be required at the discretion of the treating physician.  
 
2If CT scans of the chest, abdomen and pelvis have been collected and done within 90 days 
of C1D1 they will not be required at the screening visit. Scans will be repeated at 
cycles 6, 12, and EOT for participants wi th extramedullary disease at baseline 
defined as adenopathy >1.5 cm in any axis, and splenomegaly >15 cm in the 
craniocaudal axis.  Scans will also be repeated to confirm a complete response if the 
participant has no detectable monoclonal pr otein and had extramedullary disease at 
baseline and at the discretion of the investigator. 
 
3If a bone marrow biopsy and aspi[INVESTIGATOR_403429] 90 days of C1D1, it will not be 
repeated.  Bone marrow biopsy and aspi[INVESTIGATOR_403430] 6, 12, and EOT . 
Bone marrow biopsy and aspi[INVESTIGATOR_403431]’s discretion, and 
at any time to confirm a complete res ponse if the participan t has no detectable 
monoclonal protein. MYD88 and CXCR4 mutationa l status will be asse ssed at each bone 
marrow biopsy. 
 
4For patients who demonstrate therapy-related he matoxicity, more freque nt CBC evaluations are 
strongly recommended. 
 
5Coagulation profile. Prothrombin time (PT) will be performed at screening and repeated as 
clinically indicated. PT will be reported as well as the international normalized ratio 
(INR) and PTT.  
 6
For women of childbearing poten tial only: Serum pregnancy test  is required at screening. 
 
7Please refer to Section 6 for Dose Modifications 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
39 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508894] 
 
For the purposes of this study, par ticipants should be re-evaluat ed for response every 4 weeks ± 
1 week for cycles 1, 2, and 3 and thereafter ever y 12 weeks ± 2 weeks for the remaining cycles 
for a total of 4 years, and within 4 weeks ± [ADDRESS_508895]-treatment, 
patients will continue to be follo wed-up every 12 weeks ± [ADDRESS_508896] International Work shop on WM (Anderson et al, 2012).  
 
 
11.[ADDRESS_508897] – Hematologic Tumors 
 
11.1.1  Definitions 
 Evaluable for toxicity:  All participants who re ceive at least one dose of study treatment will 
be evaluable for toxicity from th e time of their first treatment.  
 Evaluable for objective response:  Only those participants who have measurable disease 
present at baseline, have receiv ed at least one cycl e of therapy, and have had their disease 
re-evaluated will be considered evaluable fo r response. These participants will have their 
response classified according to the definitions stated below. (Note: Participants who 
exhibit objective disease progression or die prior to  the end of cycle 1 will also be considered 
evaluable.)  11.1.2  Response Criteria  
 
Complete Response (CR): A complete response (CR) is defi ned as having resolution of WM 
related symptoms, normalization of serum IgM le vels with complete disappearance of IgM 
paraprotein by [CONTACT_5294], a nd resolution of any adenopathy or splenomegaly. A complete 
response requires reconfirmation demonstrating normal serum IgM levels, and absence of IgM 
paraprotein by [CONTACT_403471] a measurem ent repeated at least 2 weeks later. 
 Very Good Partial Response (VGPR): is defined as > 90% reducti on in serum IgM levels, or 
normalization of serum IgM levels. 
 Partial Response (PR): Partial response (PR) is defined as achieving a > 50% reduction in 
serum IgM levels. 
 Minor Response (MR): A minor response (MR) is defined 25-49% reduction in serum IgM 
levels.  Progressive Disease (PD): Progressive disease (PD)  is defined as occurring when a greater than 
25% increase in serum IgM level oc curs with an absolute increase of at least 500 mg/dL from the 
lowest attained response value, or progressi on of clinically signif icant disease related 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
40 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 symptom(s). Reconfirmation of the initial IgM incr ease is required when IgM is the sole criterion 
for progressive disease confirmation.  Death from any cause or initiation of a new anti-neoplastic 
therapy will also be considered a progression ev ent. For participants on active therapy who are 
on a drug hold for > [ADDRESS_508898] be on study drug for >2 c onsecutive weeks to be c onsidered eligible for 
serum IgM response assessment. An increase of 1 cm  in any axis for adenopathy, or 2 cm in the 
craniocaudal axis of the spleen will be considered evidence of progression of extramedullary disease. Development of Bing Neel syndrome, or other extramedullary disease manifestations, as 
well as disease transformation will be considered as progressive events. 
 Stable Disease (SD): Stable disease is defined as having < 25% change in serum IgM levels, in 
the absence of new or increasi ng adenopathy or splenomegaly and/ or other progressive signs or 
symptoms of WM. 
 
Overall Response Rate (ORR): Includes patients who achieved MR, PR, VGPR and CR. 
 
11.1.[ADDRESS_508899] scans at cycles 6, 12, 24, 36 and 48. 
 
11.1.4  Time-to-event definition 
 
 Progression-Free Survival (PFS) is defined as th e duration of time from start of treatment to 
time of objective disease progression (including initiation of new therap y or death). Median, 
2-year and 4-year landmark PFS an alysis will be determined. 
 Overall survival (OS) is define d as the duration of time from start of treatment to time of 
death or last follow-up. Median, 2-year a nd 4-year landmark OS analysis will be 
determined. 
 Time to Progression (TTP) for a given subject will be defined as the number of days from 
the date the subject started study drug to th e date of the subject' s tumor progression as 
defined in Section 11.1.1. Time to tumor progression may be collected up to [ADDRESS_508900] study visit at which a tumor assessment was performed. 
 The duration of response (DOR) for a given subject  will be defined as the number of days 
from the day the criteria are met for ORR to th e date that PD is objectively documented. The 
reference for PD will be the smallest IgM meas urements recorded since the treatment started. 
If a subject is still responding th en the subject's data will be ce nsored at the last study visit at 
which a tumor assessment was performed. 
 
12. 
DATA REPORTING / REGULATORY REQUIREMENTS 
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 
(Adverse Events: List and Reporting Requirements). 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
41 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 12.1 Data Reporting 
 
12.1.1  Method 
 
 
The Office of Data Quality (ODQ) will collect, manage, and perform quality checks on the data 
for this study.  
 
12.1.2  Responsibility for Data Submission 
 
Investigative sites within DF/HCC or DF/PCC ar e responsible for submitting data and/or data 
forms to the Office of Data Qualit y in accordance with DF/HCC SOPs. 
  
12.2 
Data Safety Monitoring 
 
The DF/HCC Data and Safety Monitoring Committ ee (DSMC) will review and monitor toxicity 
and accrual data from this study. The committee is  composed of clinical specialists with 
experience in oncology and who have no direct re lationship with the study. Information that 
raises any questions about participant safety wi ll be addressed with the Overall PI [INVESTIGATOR_252380].  The DSMC will review each protocol  up to four times a year or mo re often if required to review 
toxicity and accrual data. Information to be pr ovided to the committee may include: up-to-date 
participant accrual; current dose level informati on; DLT information; all grade [ADDRESS_508901] been repo rted; summary of all deaths occurring with 30 
days of intervention for Phase I or  II protocols; for gene therapy protocols, summary of all deaths 
while being treated and during ac tive follow-up; any response info rmation; audit results, and a 
summary provided by [CONTACT_3476]. Other information (e.g. scans, laboratory values) will be provided upon request.   
12.3 
Multicenter Guidelines 
 
This protocol will adhere to the policies and re quirements of the DF/HCC Multi-Center Data and 
Safety Monitoring Plan.  The speci fic responsibilities of the Overa ll PI, Coordinating Center, and 
Participating Institutions a nd the procedures for auditing are presented in Appendix C. 
 The Overall PI/Coordinating Center is respons ible for distributing all IND Action Letters 
or Safety Reports to all participating institu tions for submission to their individual IRBs 
for action as required. 
 
 Mechanisms will be in place to ensure quali ty assurance, protocol compliance, and 
adverse event reporting at each site. 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
42 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  Except in very unusual circumstances, each pa rticipating institution will order the study 
agent(s) directly from supplier.  A participa ting site may order the agent(s) only after the 
initial IRB approval for the site has been  forwarded to the Coordinating Center. 
 12.4 
Collaborative Agreements Language 
 
N/a 
 
13. STATISTICAL CONSIDERATIONS 
 
This is single arm, open label, Phase II study desi gned to evaluate the safety and efficacy of 
ABT-199 in previously treated, relapsed/refractor y WM patients. Therapy will be administered 
daily to patients with WM, and patients will re ceive treatment until progression or unacceptable 
toxicity for 2 years after comp letion of the lead-in phase.  
 Study Design/Endpoints  The primary endpoint of the current study is: 
 
 To assess the overall response rate (ORR) of  ABT-199 in symptomatic WM patients with 
relapsed/refractory disease. 
 The final analysis for the primary endpoint, overa ll response rate (minor response or better), will 
be conducted at [ADDRESS_508902] had adequate assessment.  13.1 
Study Design/Endpoints 
 
The primary endpoint of this study is to assess the Overall Response Rate (MR or better).  Major 
response rates ( PR or better ), and Very Good Partial Response/Complete Response (VGPR/CR) of 
ibrutinib in previously treated, symptomatic WM patients  will also be evaluated.  The analysis for 
the primary endpoint, Overall response rate (MR or better), will be based on the evaluable 
population. The evaluable population will be defined as all enroll ed participants. The overall 
response rate and its exact 95% confidence intervals (C I) will be calculated and the null 
hypothesis will be rejected if the lower bound of the 95% confidence interval exceeds 40% . The 
analysis for major response (PR or better) will be similarly ev aluated. In add ition, the number 
and percent of subjects by [CONTACT_403472] (CR, VGPR, PR, MR, SD, or PD) will be 
summarized.     13.2 
Sample Size, Accrual Ra te and Study Duration 
 
Following a Fleming’s one step approach, and assuming a null (H0) ORR of 40% (based on 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
43 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 previous experience on single-agent efficacy in pa tients with WM), and an alternative (H1) ORR 
of 70%, a total of 30 evaluable patients need to  be accrued to show the proposed difference with 
an alpha (type I error) of 0.04 and a power (1-beta or type II error) of 90%, based on a binomial 
model (STATA version 13.1). [ADDRESS_508903] a 
minor response (18/30 patients ORR 60%, 95% CI 42-75%), the null hypothesis will be rejected 
and further research with ABT- 199 in patients with WM woul d be warranted.  The expected 
accrual rate is 2-4 part icipants per month, for a an exp ected accrual time of 9-12 months. 
  13.3 
Stratification Factors 
 
  No stratification factors w ill be applied to any analysis. 
 13.4 
Interim Monitoring Plan 
 
Refer to section 13.6 
 13.5 
Analysis of Primary Endpoints 
 
Refer to section 13.6  
13.6 
Analysis of Secondary Endpoints 
 
The secondary endpoints are: 
 
 To assess the safety and tolerability of ABT-199 in symptomatic WM patients with 
relapsed/refractory disease. 
 To evaluate the rate of CR, very good part ial response (VGPR), pa rtial response (PR), 
minimal response (MR), stable disease (SD) and progressive disease (PD)  
 To evaluate the median, 2-y ear and 4-year PFS and OS, and median duration of response 
(DOR) 
 To evaluate the toxicity profile of ABT- 199 in patients with relapsed/refractory WM 
 To determine the MYD88 L265P mutational status  in response to ABT-199 in patients with 
relapsed/refractory WM 
 To evaluate the association between depth of response and quantification of MYD88 L265P 
burden by [CONTACT_954] 
 To evaluate the association between presence of CXCR4-WH IM-like mutations and response 
to ABT-[ADDRESS_508904] by [CONTACT_2054]. Analysis of TTP, DOR, PFS and OS analysis will be 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
44 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 conducted at the same cutoff as the overall respon se rate, and an update of these endpoints will 
be provided at the end of the study.  In recent studies, the MYD88 and CXCR4 mutati onal status are predictiv e of clinical status, 
response to therapy and survival outcome s (Cao 2013, Treon 2013, Treon 2014). Activating 
MYD88 as well as nonsense and frameshift WH IM-like CXCR4 somatic mutations are common 
in Waldenström macroglobulinemia. CXCR4 nonsense  mutations are present in aggressive cases 
including hyperviscosity syndrom e, and MYD88 status is a dete rminant of survival. The MYD88 
L265P mutational analysis by [CONTACT_403473]-specific PCR and CXCR4 mutational analysis by [CONTACT_403474]öm Macroglobulinemia in 
[LOCATION_011], MA. 
13.[ADDRESS_508905] receive copi[INVESTIGATOR_403432] (at least fifteen working days for 
presentational materials and abstracts and th irty working days for manuscripts). These 
requirements acknowledge Abbvie, Inc.’s responsi bility to provide peer  input regarding the 
scientific content a nd conclusions of such publicati ons or presentations. Principal 
Investigation/Institution shall have the final auth ority to determine the sc ope and content of its 
publications, provided such authority shall be exer cised with reasonable regard for the interests 
of Abbvie, Inc. and, in accord w ith the trial contract and shall not permit disclosure of Abbvie, 
Inc. confidential or proprietary information.   Abstracts will be submitted, and presented if accep ted as poster or oral presentation, at the ASH 
Annual Meeting and at the EHA Annual Meetin g on a yearly basis while the study is ongoing. 
The final manuscript will be compi[INVESTIGATOR_403433] d for publication in approximately 2 years of 
the end date of all data colle ction with an updated publication at 4-year landmark analysis. 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
45 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 REFERENCES 
 
Bajwa N, Liao C, Nikolovska-Coleska Z. Inhibitors  of the anti-apoptotic Bc l-2 proteins: a patent 
review. Expert Opin Th er Pat 2012; 22: 37-55. 
 Cao Y, Hunter ZR, Liu X, et al. The WHIM -like CXCR4(S338X) somatic mutation activates 
AKT and ERK, and promotes resistance to ibru tinib and other agents in the treatment of 
Waldenstrom’s Macroglobulinemia. Leukemia 2014 [Epub ahead of print]  Castillo JJ, Olszewski AJ, Cronin AM, et al. Su rvival trends in Waldenström macroglobulienia: 
an analysis of the Surveill ance, Epi[INVESTIGATOR_403434]. Blood 2014; 123(25): 
3999-4000.  Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-199) in patients 
with relapsed/refractory (R/R ) non-Hodgkin lymphoma (NHL): Re sponses observed in diffuse 
large B-cell (DLBCL) and follicul ar lymphoma (FL) at higher cohort doses. J Clin Oncol 
(Meeting Abstracts) 2104; 32(15_s): 8522.  Fesik SW. Promoting apoptosis as a strategy for cancer drug discover y. Nat Rev Cancer 2005; 
5(11): 876-85.  Gertz MA, Geyer SM, Badros A et al. Early results of a phase I trial of oblimersen sodium for 
relapsed or refractory Waldenstrom's macr oglobulinemia. Clin Lym phoma 2005; 5: 282-284. 
 Hatjiharissi E, Mitsiades CS, Bryan CT et al . Comprehensive Molecular Characterization of 
Malignant and Microenvironmental Cells in  Waldenstrom's Macroglobulinemia by [CONTACT_403475]. ASH Annual M eeting Abstracts 2007; 110: 3174-. 
 Hunter ZR, Xu L, Yang G, et al. The genomic  landscape of Waldenstrom macroglobulinemia is 
characterized by [CONTACT_403476]88 and WHIM-like CXCR4 mutations, and small somatic 
deletions associated with B-cell ly mphomagenesis. Blood 2014; 123(11): 1637-46. 
 Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and crit eria to initiate therapy in 
Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second 
International Workshop on Waldenstrom's Macr oglobulinemia. Semin Oncol 2003; 30(2): 116-
20.  Leleu X, Soumerai J, Roccaro A et al. In creased incidence of transformation and 
myelodysplasia/acute leukemia in patients with  Waldenstrom macroglobulinemia treated with 
nucleoside analogs. J Clin Oncol 2009; 27: 250-255. 
 Ogmundsdottir HM, Einarsdottir HK, Steingrim sdottir H, Haraldsdottir V. Familial 
predisposition to monoclonal gammopat hy of unknown significance, Waldenstrom's 
macroglobulinemia, and multiple myeloma. Clin Lymphoma Myeloma 2009; 9: 27-29. 
 Owen RG, Treon SP, Al-Katib A, et al. Clin icopathological definition of Waldenström’s 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
46 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Macroglobulinemia: consensus panel recommendati ons from the Second International Workshop 
on Waldenström’s Macroglobulinemia. Semin Oncol 2003; 30(2): 110-115. 
 Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström 
macroglobulinaemia: update from the VIth Intern ational Workshop. Br J Haematol 2013; 160(2): 
171-6. 
 Paulus A, Chitta K, Akhtar S et al. AT-101 dow nregulates BCL2 and MCL1 and potentiates the 
cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol 2014; 164: 352-365. 
 San Miguel JF, Vidriales MB, Ocio E et al . Immunophenotypic analysis  of Waldenstrom's 
macroglobulinemia. Semin Oncol 2003; 30: 187-195.  Sekhar J, Sanfilippo K, Zhang Q, et al. Wald enström macroglobulinem ia: a Surveillance, 
Epi[INVESTIGATOR_623], and End Results database re view from 1988 to 2005. Leuk Lymphoma 2012; 
53(8): 1625-6.  Seymour JF, Davids MS, Pagel JM, et al. ABT- 199 (GDC-199) in rela psed/refractory (R/R) 
chronic lymphocytic leukemia (CLL) and sma ll lymphocytic lymphoma (SLL): High complete 
response rate and durable disease control. J Clin Oncol (Meeting Abstracts) 2014; 32(15_s): 
7015.  Souers AJ, Leverson JD, Boghaert ER et al. AB T-199, a potent and selective BCL-2 inhibitor, 
achieves antitumor activity while spari ng platelets. Nat Med 2013; 19: 202-208. 
  Swerdlow SH, Berger F, Pi[INVESTIGATOR_403435]. Lymphoplasmacytic lymphoma. In Swerdlow SH, 
Campo E, Harris NL et al. (eds): WHO Cla ssification of Tumours of Haematopoietic and 
Lymphoid Tissues. Lyon, [LOCATION_009]: IARC 2008; 194-195. 
 Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009;114(12):2375-85. 
 
Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's 
macroglobulinemia. N Engl J Med 2012; 367(9): 826-33.  
Treon SP, Tripsas CK, Yang G, et al. A prospec tive multicenter study of the Bruton’s Tyrosine 
Kinase inhibitor ibrutinib in patients w ith relapsed or refractory Waldenstrom’s 
Macroglobulinemia. ASH Annual Mee ting Abstracts 2013; 122(21): 251. 
 
Treon SP, Cao Y, Xu L, et al. Somatic mutati ons in MYD88 and CXCR4 are determinants of 
clinical presentation and overall survival in Waldenstrom’s macroglobulinemia. Blood 2014; 
123(18): 2791-6. 
 Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of 
lymphoplasmacytic cells by [CONTACT_403477] . Blood 2013; 122(7): 1222-32.
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
47 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  
APPENDIX A PERFORMANCE STATUS CRITERIA 
 
ECOG Performance Status Scale Karnofsky Performance Scale 
Grade Descriptions Percent Descriptio n 
0 Normal activity.  Fully active, able 
to carry on all pre-disease performance without restriction. 100 Normal, no complaints, no evidence 
of disease.
90 Able to carry on normal activity; 
minor si gns or s ymptoms of disease.
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 80 Normal activity with effort; some 
signs or symptoms of disease. 
70 Cares for self, unable to carry on 
normal activity or to do active work.
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. [ADDRESS_508906] of his/her needs.
50 Requires considerable  assistance and 
frequent medical care. 
3 In bed >50% of the time.  Capable 
of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and 
assistance.
30 Severely disabled, hospi[INVESTIGATOR_373].  Death not imminent.
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 20 Very sick, hospi[INVESTIGATOR_374]. 
Death not imminent. 
10 Moribund, fatal processes 
progressin g rapi[INVESTIGATOR_2478] y. 
5 Dead. 0 Dead.
           
 
   
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
48 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 APPENDIX B: Recommendations for Initial Manageme nt of Electrolyte Abnormalities and 
Prevention of Tumor Lysis Syndrome (TLS)  Section 1: First Dose of ABT-199 or Dose Escalation  
 Within the first [ADDRESS_508907] dose or dose escalation, if any laboratory 
criteria below are met, the patient should be hospi[INVESTIGATOR_403436]. No additional ABT-199 doses should be administered until resolution. Rapi[INVESTIGATOR_403437] a medical emergency. 
 Nephrology (or other acute dialysis service) s hould be contact[INVESTIGATOR_530]/consulted (per institutional 
standards to ensure emergency dialysis is available) on admission for any subject 
hospi[INVESTIGATOR_403438]. 
 IV fluids (e.g., D5 1/2 normal saline) should be initiated at a rate of  at least 1 mL/kg/hr 
rounded to the nearest 10 mL (target 150 to 200 mL/hr; not < 50 mL/hr). Modification of 
fluid rate should also be considered for individuals with specific medical needs. 
 Monitor for symptoms or signs of TLS (e.g., fever, chills, tachycardia, nausea, vomiting, 
diarrhea, diaphoresis, hypotensi on, muscle aches, weakness, pa resthesias, mental status 
changes, confusion and seizures). If any clin ical features are obser ved, recheck potassium, 
phosphorus, uric acid, calcium and creatinine within 1 hour STAT. 
 Vital signs should be taken at time of  all blood draws or any intervention. 
 The management recommendations below focu s on the minimum initial responses required. 
If a diagnosis of TLS is established, ongoing intensive monitoring and multi-disciplinary management will be per institutional protocols.  
 In addition to the recommendations in the table below, for subjects receiving the first dose of 
ABT-199:  
 For potassium increase ≥ 0.5 mmol/L from baseline, or any value > 5.0 mmol/L, recheck 
potassium, phosphorus, uric acid, calcium and cr eatinine within [ADDRESS_508908] 
guideline. 
 For phosphorus increase of > 0.5 mg/dL AND > 4.5 mg/dL, administer phosphate binder and 
recheck potassium, phosphorus, uric acid, calc ium and creatinine within 1 hour STAT.  
 
Abnormality Management recommendation 
Hyperkalemia (Includi ng rapi[INVESTIGATOR_403439])  
Potassium ≥ 0.5 mmol/L increase from prior 
value (even if potassium within normal limits [WNL])   Recheck potassium, phosphorus, uric acid, 
calcium and creatinine in 1 hour STAT. If 
further ≥ 0.2 mmol/L increase in potassium, 
but still < upper limit of normal 
 (ULN), manage as per potassium ≥ ULN. 
Otherwise recheck in 1 hour. 
 Resume per protocol testing if change in 
potassium is < 0.2 mmol/L, and potassium 
< ULN, and no other evidence of tumor 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
49 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 lysis. 
 At the discretion of the investigator, may 
recheck prior to hospi[INVESTIGATOR_1916]. If stable or 
decreased, and still WN L, hospi[INVESTIGATOR_403440]. 
 Potassium, phosphorus, uric acid, calcium 
and creatinine must be rechecked within 24 
hours.
Potassium > upper limit of normal   Perform STAT ECG and commence 
telemetry. 
 Nephrology (or other acute dialysis 
service) notification wi th consideration of 
initiating dialysis. 
 Administer Kayexalate  60 g (or Resonium 
A 60 g). 
 Administer furosemide 20 mg IV × 1. 
 Administer calcium gluconate 100 to 200 
mg/kg IV slowly if there is ECG/telemetry evidence of life-threatening arrhythmias. 
 Recheck potassium, phosphorus, uric acid, 
calcium and creatinine in 1 hour STAT. 
 If potassium < ULN 1 hour later, repeat 
potassium, phosphorus, uric acid, calcium and creatinine 1, 2 and 4 hrs., if no other evidence of tumor l
ysis. 
Potassium ≥ 6.0 mmol/L (6.0 mEq/L) and/or 
symptomatic (e.g., muscle cramps, weakness, paresthesias, nausea, vomiting, diarrhea)   Perform STAT ECG and commence 
telemetry. 
 Nephrology (or other acute dialysis 
service) assessment with consideration of initiating dialysis. 
 Administer Kayexalate  60 g (or Resonium 
A 60 g). 
 Administer furosemide 20 mg IV × 1. 
 Administer insulin 0.1 U/kg IV + D25 2 
mL/kg IV. 
 Administer sodium bicarbonate 1 to 2 
mEq IV push. 
 If sodium bicarbonate is used, rasburicase 
should not be used as this may exacerbate 
calcium phosphate precipi[INVESTIGATOR_332]. 
 Administer calcium gluconate 100 to 200 
mg/kg IV slowly if there is ECG/telemetry evidence of life-threatening arrhythmias. Do not administer in same IV line as sodium bicarbonate. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
50 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  Recheck potassium, phosphorus, uric acid, 
calcium and creatinine ever y hour STAT.
Hyperuricemia  
Uric acid ≥ 8.0 mg/dL (476 μmol/L)   Consider rasburicase (dose based on local 
guidelines and/or inst itutional standards). 
 If rasburicase is used, sodium bicarbonate 
should not be used as this may exacerbate 
calcium phosphate precipi[INVESTIGATOR_332]. 
 Recheck potassium, phosphorus, uric acid, 
calcium and creatinine in 1 hr STAT.
Uric acid ≥ 10 mg/dL (595 μmol/L) 
 OR  Uric acid ≥ 8.0 mg/dL (476 μmol/L) with 25% 
increase and creatinine increase ≥ 0.3 mg/dL ( ≥ 
0.027 mmol/L) from pre-dose level   Administer rasburic ase (dose based on 
local guidelines and/or institutional standards). 
 When rasburicase is used, sodium 
bicarbonate should not be used as this may 
exacerbate calcium phosphate precipi[INVESTIGATOR_332]. 
 Notify nephrology (or other acute dialysis 
service). 
 Recheck potassium, phosphorus, uric acid, 
calcium and creatinine in 1 hour STAT. 
 If uric acid < 8.0 mg/dL 1 hour later, 
repeat potassium, phos phorus, uric acid, 
calcium and creatinine 2 and 4 hrs. later, if 
no other evidence of tumor l
ysis. 
Hypocalcemi a 
Calcium ≤ 7.0 mg/dL 
(1.75 mmol/L) AND Patient symptomatic (e.g., muscle cramps, hypotension, tetany, cardiac arrhythmias)  Administer calcium gluconate 50 to 100 
mg/kg IV slowly with ECG monitoring. 
 Telemetry. 
 Recheck potassium, phosphorus, uric acid, 
calcium and creatinin e in 1 hr STAT. 
 If calcium normalized 1 hour later, repeat 
potassium, phosphorus, uric acid, calcium 
and creatinine 2 and 
 4 hrs. later, if no ot her evidence of tumor 
lysis. 
 Calculate corrected calcium and check 
ionized calcium if albumin low. 
Hyperphosphatemia 
Phosphorus ≥ 5.0 mg/dL 
(1.615 mmol/L) with ≥ 0.5 mg/dL 
(0.16 mmol/L) increase  Administer a phos phate binder (e.g., 
aluminum hydroxide, calcium carbonate, sevelamer hydroxide, or lanthanum carbonate). 
Nephrolo gy (or other acute dial ysis 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
51 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 service) notification (dialysis required for 
phosphorus ≥ 10 mg/dL). 
 Recheck potassium, phosphorus, uric acid, 
calcium and creatinine in 1 hr STAT 
 If phosphorus < 5.0 mg/dL 1 hour later, 
repeat potassium, phos phorus, uric acid, 
calcium and creatinine 2 and 4 hrs., later, 
if no other evidence of tumor l ysis.
Creatinine 
Increase ≥ 25% from baseline  Start or increase rate of IV fluids. 
 Recheck potassium, phosphorus, uric acid, 
calcium and creatinine in 1 to 2 hours 
STAT.
 Section 2: Ongoing Dosing of ABT-[ADDRESS_508909] va lue at intervals > [ADDRESS_508910] 
dose or dose escalation (e.g., 48 or  72 hours) are as below. 
 Note: If the patient is hospi[INVESTIGATOR_190313], no additional ABT-199 doses should be administered until 
resolution.  
 For potassium, admit patient for any increase ≥ 1.0 mmol/L (1.0 mEq/ L), or any level > 
upper limit of normal. 
 Refer to the management guidelines for electr olyte changes observed within the first [ADDRESS_508911] dose or  dose escalation (s ee prior table). 
 If a smaller potassium increase is observed th at does not meet the criteria for admission 
above, recheck potassium, phosphorus, uric ac id, calcium and creatinine in 24 hours and 
confirm no evidence of tumor lysis prior to further ABT-199 dosing. 
 For uric acid, calcium, phosphorus and creatinin e, refer to the management guidelines for 
electrolyte changes observed within the first [ADDRESS_508912] dose or dose 
escalation (see prior table).  
 
 
          
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
52 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 APPENDIX C.  DEFINITIONS OF LABORATORY AND CLINICAL TUMOR LYSIS SYNDROME   
 
Metabolic      Criteria for Classification of                        Criteria for Classification of  
Abnormality                 Laboratory Tumor Lysi s Syndrome             Clinical Tumor Lysis Syndrome  
 
 
Hyperruricemia              Uric acid > 8.0 mg/dl (475.8µmol/liter)   
                                        in adults or above the upper limit of the 
                                        normal range for age in children  
 
Hyperphosphatemia       Phosphorus > 4.5 mg/dl (1.5mmol/liter)  
                                        in adults or > 6.5 mg/dl (2.1 mmol/liter)                                           in children 
 
Hyperkalemia                 Potassium > 6.0 mmol/liter                             Cardiac  dysrhythmia or sudden death
                                           
                                                                              probably or definitely caused by                                
                              [CONTACT_403478] < 7.0 mg/dl                        Cardiac dysrhythmia, sudden death,  
                    (1.75 mmol/liter) or ionized calcium              seizure, neuromuscular irritability  
                   <1.12 (0.3 mmol/liter) †          (tetany, paresthesias, muscle twitching, 
         C a r p o p e d a l  spasm, Trousseau’s sign,  
                              Chvostek’s sign, laryngospasm, or 
         bronchospasm), hypotension, or heart          failure probably or definitely caused by          [CONTACT_403479]. 
 
Acute kidney injury
‡      Not Applicable                             Increase in the serum creatinine   level 
of  0.3 mg/dl (26.5 µmol/liter) (or a               
single value > 1.5 times the upper limit of the age-appropriate normal range if no baseline creatinine measurement is 
available) or the pr esence of oliguria, 
defined as an average urine output < 0.5 ml/kg/hr for 6 hrs 
 
 
 
†     The corrected calcium level in milligrams per deciliter = measured calcium level in milligrams per deciliter + 0.8 × (4-  
albumin in grams per deciliter). 
‡      Acute kidney injury is definited as an increase in the creatinine level of at least 0.3 mg per deciliter (26.5 µmol per liter) or 
a period of oliguia lasting 6 hours or more. By [CONTACT_108], if ac ute kidney injury is present, the patient has clinical tumor l ysis 
syndrome. Data about acute kidn ey injurt from Levin at al. 
 
Note:       In laboratory tumor lysis syndrome, two or more metabolic abnormalities mu st be present during the same 
24-hour period within [ADDRESS_508913]. Clinical tumor lysis syndrome requires 
the presence of laboratory tumor lysis syndrome plus an increased creatinine level, seizures, cardiac dysrhythmia, or death. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
53 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 APPENDIX D MULTICENTER GUIDELINES 
 
 
DFCI IRB Protocol #: 15-491  
 
  
 
 
APPENDIX D 
 
Dana-Farber/Harvard Cancer Center 
Multi-Center Data and Safety Monitoring Plan 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
54 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 TABLE OF CONTENTS 
15. INTRODUCTION .............................................................................................................55  
15.1 Purpose ...................................................................................................................55  
15.2 Multi-Center Data and Safety Monitoring Plan Definitions ..................................55  
16. GENERAL ROLES AND RE SPONSIBILITIES .............................................................56  
16.1 DF/HCC Sponsor ...................................................................................................56  
16.2 Coordinating Center ...............................................................................................57  
16.3 Participating Institution ..........................................................................................57  
17. DF/HCC REQUIREMENTS FOR MU LTI-CENTER PROTOCOLS..............................58  
17.1 Protocol Distribution ..............................................................................................58  
17.2 Protocol Revisions  and Closures ...........................................................................58  
17.3 Informed Consent Requirements ...........................................................................59  
17.4 IRB Documentation ...............................................................................................59  
17.5 IRB Re-Approval ...................................................................................................59  
17.6 Participant Confidentiality a nd Authorization Statement ......................................60  
17.7 DF/HCC Multi-Center Protoc ol Registration Policy .............................................60  
17.8 DF/HCC Protocol Case Number ............................................................................61  
17.9 Safety Assessments and Toxicity Monitoring .......................................................63  
17.10 Data Management ..................................................................................................63  
18. REQUISITIONING INVESTIGATIONAL DRUG..........................................................64  
19. MONITORING: QUALITY CONTROL ..........................................................................64  
19.1 Ongoing Monitoring of Protocol Compliance .......................................................64  
19.2 Monitoring Reports ................................................................................................65  
19.3 Accrual Monitoring ................................................................................................66  
20. AUDITING: QUALITY ASSURANCE ...........................................................................66  
20.1 Audit Plan: NCI Sponsored Trials .........................................................................66  
20.2 Audit Plan: DF/HCC Sponsored Trials..................................................................66  
20.3 Audit Notification ..................................................................................................66  
20.4 Audit Reports .........................................................................................................66  
20.5 Participating Institution Performance ....................................................................67  
 
  
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
55 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  
15. INTRODUCTION 
 
The Dana-Farber/Harvard Cancer Center Multi- Center Data and Safety Monitoring Plan 
(DF/HCC DSMP) outlines the procedures for conducting a DF/HCC Mu lti-Center research 
protocol. The DF/HCC DSMP shou ld serve as a reference for any sites external to DF/HCC 
that will be participating in the research protocol. 
 
15.1 Purpose 
 
To establish standards that will ensure that  a Dana-Farber/Harvard Cancer Center Multi-
Center protocol will comply with Federal Regulations, Health Insu rance Portability and 
Accountability Act (HIPAA) requirements and applicable DF/HCC Standard Operating 
Procedures .        
 
15.2 Multi-Center Data and Safety Monitoring Plan Definitions 
 
DF/HCC Multi-Center Protocol :  A research protocol in which one  or more outside 
institutions are collaborating with Dana-Farbe r/Harvard Cancer Center where  a DF/HCC 
investigator is the sponsor. DF /HCC includes Dana-Farber/Partners Cancer Care (DF/PCC) 
Network Clinical Trial Affiliates.  
 Lead Institution:  One of the  Dana-Farber/Harvard Cancer Center consortium members 
(Dana-Farber Cancer Institute (DFCI), [LOCATION_005] General Hospi[INVESTIGATOR_307] (MGH), Beth Israel Deaconess Medical Center (BIDMC), [LOCATION_011] Children’s Hospi[INVESTIGATOR_307] (BCH), Brigham 
and Women’s Hospi[INVESTIGATOR_307] (BWH)) responsible  for the coordination, development, 
submission, and approval of a protocol as we ll as its subsequent amendments per the 
DFCI IRB and applicable regulatory guide lines (CTEP, Food and Drug Administration 
(FDA), Office of Biotechnology Activities (OBA) et c.).  The Lead Institution is typi[INVESTIGATOR_345892]/HCC Sponsor. The Lead In stitution also typi[INVESTIGATOR_403441] /HCC Multi-Center Protocol.   
 DF/HCC Sponsor:  The person sponsoring the submitted Mu lti-Center protocol.  Within 
DF/HCC, this person is the Overall Principa l Investigator who ta kes responsibility for 
initiation, management and conduct of the protocol  at all research loca tions. In applicable 
protocols, the DF/HCC Sponsor will serve as the single liaison with any regulatory agencies (FDA) . The DF/HCC Sponsor has ultimate auth ority over the protocol and is 
responsible for the conduct of the study at DF/H CC and all Participating Institutions. In 
most cases the DF/HCC Sponsor is the same  person as the DF/HCC Overall Principal 
Investigator; however, both roles can be filled by [CONTACT_57945].  
 
Participating Institution:  An institution that is outside the DF/HCC and DF/PCC 
consortium that is collabor ating with DF/HCC on a protoc ol where the sponsor is a 
DF/HCC Investigator.  The Participating Institution ac knowledges the DF/HCC Sponsor 
as having the ultimate authorit y and responsibility for the overa ll conduct of the study.    
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
56 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Coordinating Center: The entity (i.e. Lead Institution, Medical Monitor, Contract 
Research Organization (CRO), etc) that provides administra tive support to the DF/HCC 
Sponsor in order that he/she may fulfill th e responsibilities outlined in the protocol 
document and DSMP, and as specified in app licable regulatory gui delines (i.e. CTEP 
Multi-Center Guidelines). In general, the L ead Institution is the Coordinating Center for 
the DF/HCC Multi-Center Protocol. Should th e DF/HCC Sponsor deci de to use a CRO, 
the CRO will be deemed the Coordinating Center.    DF/HCC Office of Data Quality/Clinical Trial Research Informatics Office: Groups 
within DF/HCC responsible for registering hum an subjects for trials, ensuring high-quality 
standards are used for data collection and the ongoing manage ment of clinical trials, 
auditing, and data and safety monitoring. ODQ al so coordinates quality  assurance efforts 
related to multi-center clinical research.  
 16. 
GENERAL ROLES AND RESPONSIBILITIES 
For DF/HCC Multi-Center Protocols, the DF /HCC Sponsor, the Coordinating Center, and 
the Participating Institutions are expected to adhere to the following general responsibilities:  
 
16.1 
DF/HCC Sponsor 
 
The DF/HCC Sponsor, Jorge J. Castillo, will accept responsibilit y for all aspects of 
conducting a DF/HCC Multi-Center protocol wh ich includes but is not limited to:  
 Oversee the coordination, development, submission, and approval of the protocol 
as well as subsequent amendments.  
 Ensure that the investigators, study team  members, and Participating Institutions 
are qualified and appropriately resour ced to conduct the protocol.   
 Include the Multi-Center Data and Safety Monitoring Plan as an appendix to the 
protocol. 
 Ensure all Participating Institutions are using the correct vers ion of the protocol. 
 Ensure that each participating investig ator and study team member receives 
adequate protocol training and/or a Si te Initiation Visit prior to enrolling 
participants and throughout trial’s conduct as needed. 
 Ensure the protocol will be provided to each particip ating site in a language 
understandable to all appli cable site personnel when English is not the primary 
language.  
 Monitor progress and overall conduct of the study at all Participating Institutions.  
 Ensure all DFCI Institutional Review Bo ard (IRB), DF/HCC and other applicable 
(i.e. FDA)  reporting requirements are met.  
 Review data and maintain timely subm ission of data for study analysis.  
 Act as the single liaison with FDA (investigator-held IND trials, as applicable . 
 Ensure compliance with all requirements as set forth in the Code of Federal 
Regulations, applicable DF/HCC require ments, HIPAA requirements, and the 
approved protocol. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
57 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  Commit to the provision that the protocol  will not be rewritten or modified by 
[CONTACT_57946]/HCC Sponsor. 
 Identify and qualify Participating Institutions and obtain accrual commitments 
prior to extending the pr otocol to that site. 
 Monitor accrual and address Participating Institutions that are not meeting their 
accrual requirements.  
 
16.2 Coordinating Center  
 
The general responsibilit ies of the Coordinating Center ma y include but are not limited to: 
 Assist in protocol development.  
 Maintain FDA correspondence, as applicable . 
 Review registration materials for eligib ility and register participants from 
Participating Institutions with OnCore 
 Distribute protocol and informed consent document updates to Participating 
Institutions as needed. 
 Oversee the data collection proce ss from Participating Institutions. 
 Maintain documentation of Serious  Adverse Event (SAE) reports and 
deviations/violation submitted by [CONTACT_102858]/HCC Sponsor for timely review.   
 Distribute serious adverse events reported to the DF/H CC Sponsor that fall under 
the DFCI IRB Adverse Event Reporting Po licy to all Participating Institutions. 
 Provide Participating Institutions w ith information regarding DF/HCC 
requirements that they will be expected to comply with.  
 Carry out plan to monitor Participating In stitutions either by [INVESTIGATOR_2394]-site or remote 
monitoring.  
 Maintain Regulatory documents of all Part icipating Institutions which includes but 
is not limited to the following: local IRB approvals/notifications from all Participating Institutions, confirmation of  Federalwide Assurances (FWAs) for all 
sites,  all SAE submissions, Screening L ogs for all sites, IRB approved consents 
for all sites 
 Conduct regular communications with all Participating Institutions (conference 
calls, emails, etc) and maintain docum entation all releva nt communications. 
 
16.3 
Participating Institution 
 
Each Participating Institution is expected to comply with all applicable federal regulations 
and DF/HCC requirements, the prot ocol and HIPAA requirements.  
 
The general responsibilities for each Particip ating Institution may include but are not 
limited to: 
 Document the delegation of research specific activities to study personnel. 
 Commit to the accrual of participants to the protocol. 
 Submit protocol and/or amendm ents to their local IRB. 
 Maintain regulatory files as per sponsor requirements. 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
58 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015  Provide the Coordinating Ce nter with regulatory documents or source documents 
as requested. 
 Participate in protocol trai ning prior to enroll ing participants and throughout the 
trial as required (i.e . teleconferences). 
 Update Coordinating Center with res earch staff changes on a timely basis. 
 Register participants through the Coordina ting Center prior to beginning research 
related activities.  
 Submit Serious Adverse Event (SAE) report s to local IRB per local requirements 
and to the Coordinating Center, in accordance with DF/HCC requirements.   
 Submit protocol deviations and violations to local IRB per local requirements and 
to the DF/HCC Sponsor in accordance with DF/HCC requirements. 
 Order, store and dispense investigationa l agents and/or other protocol mandated 
drugs per federal guidelines and protocol requirements. 
 Have office space, office equipment, and internet access that meet HIPAA 
standards. 
 Participate in any quality assurance activitie s and meet with monitors or auditors at 
the conclusion of a visit to review findings. 
 Promptly provide follow-up and/or corre ctive action plans for any monitoring 
queries or audit findings. 
 17. 
DF/HCC REQUIREMENTS FO R MULTI-CENTER PROTOCOLS 
 
The following section will clarify DF/HCC Require ments and further detail the expectations 
for participating in a DF/HCC Multi-Center protocol.  
 
17.1 Protocol Distribution 
 
The Coordinating Center will distribute the final DFCI IR B approved protocol and any 
subsequent amended protocols to al l Participating Institutions.    
 
17.2 Protocol Revisions and Closures 
 
The Participating Institutions will receive not ification of protocol revisions and closures 
from the Coordinating Center.  It is the individual Participa ting Institution’s responsibility 
to notify its IRB of these revisions. 
 
 Non life-threatening revisions:  Participating Institutions will receive written 
notification of protocol re visions regarding non life-th reatening events from the 
Coordinating Center. Non-life-threaten ing protocol revisions must be IRB 
approved and implemented within 90 days from receipt of the notification. 
 
 Revisions for life-threatening causes:  Participating Institu tions will receive 
immediate notification from the Coordinati ng Center concerning protocol revisions 
required to protect lives w ith follow-up by [CONTACT_6791], mail, e-mail, etc.  Life-threatening 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
59 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508914] for 
approval. 
 
 Protocol closures and temporary holds:  Participating Institutions will receive 
notification of protocol closures and temporary hol ds from the Coordinating 
Center. Closures and holds  will be effective imme diately.  In addition, the 
Coordinating Center, will update the Par ticipating Institutions on an ongoing basis 
about protocol accrual data so that they will be aw are of imminent protocol 
closures. 
 
17.3 Informed Consent Requirements 
 
The DF/HCC approved informed consent doc ument will serve as a template for the 
informed consent for Participating Institutions. The Participating Institution consent form must follow the consent template as closely as  possible and should adhe re to specifications 
outlined in the DF/HCC Guidance Document on Model Consent Language for PI-Initiated 
Multi-Center Protocols.  This document will be  provided separately to each Participating 
Institution.  Participating Institutions are to send their version of the informed consent document and HIPAA authorization, if a separate document , to the Coordinating Center for review and 
approval prior to submission to their local I RB. The approved consent form must also be 
submitted to the Coordinating Center after approval by [CONTACT_57948].  The Principal Investigator (PI)  at each Participating Instit ution will iden tify the physician 
members of the study team who will be obtai ning consent and signing the consent form 
for therapeutic protocols. Participating inst itutions must follow the DF/HCC requirement 
that only attending physicians obtain informed  consent and re-consent to interventional 
trials (i.e. drug and/or  device trials).   
 
17.[ADDRESS_508915] be on file with the Coordinating Center: 
 Initial approval letter of the Participating Institution's IRB.  
 Copy of the Informed Consent Form(s) approved by [CONTACT_57949]’s 
IRB.  
 Participating Institution’s I RB approval for all amendments. 
 Annual approval letters by [CONTACT_403480]'s IRB. 
 
 
17.5 IRB Re-Approval 
 
Verification of IRB re-approval from the Particip ating Institutions is required in order to 
continue research activities.  There is no grace period for continuing approvals.  
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
60 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508916] ( HIPPA). Any 
information, related to the physical or mental health of an individual is called Protected 
Health Information (PHI). HIPAA outlines how and under what circumstances PHI can be 
used or disclosed.  
 In order for covered entities to use or disclo se protected health in formation during the 
course of a study, the study participant must sign an authorization statement.  This 
authorization statement may or may not be separate from the informed consent document.  
The Coordinating Center, with the approval fr om the DFCI IRB, will provide a consent 
template, with information regarding authorizat ion for the disclosure of protected health 
information.   The DF/HCC Sponsor will use all efforts to limit its use of protected health information in 
its trials. However, because of the nature of these trials, certain protected health 
information must be collected. DF/HCC has c hosen to use authorizations, signed by [CONTACT_163917], rather than lim ited data sets with data use agreements. 
 
17.6.1   DF/HCC Multi-Center Protocol Confidentiality 
 
All documents, investigative reports, or inform ation relating to the participant are strictly 
confidential. Whenever reasona bly feasible, any participant specific reports (i.e. Pathology 
Reports, MRI Reports, Operative Reports, et c.) submitted to the Coordinating Center 
should be de-identified. It is recommende d that the assigned DF/HCC ODQ/OnCore case 
number (as described below) be used for all participant specific documents. Participant initials may be included or retained fo r cross verification of identification.  
 
17.7 DF/HCC Multi-Center Protoc ol Registration Policy 
 
17.7.1   Participant Registration and Randomization  
To register a participant, the following documents should be completed by [CONTACT_403481] ([PHONE_8345]) or e-mailed 
([EMAIL_7713]) to the Coordinating Center  
 Copy of serum protein elec tropheresis, CBC with diff, Chemistries, CT C/A/P, 
bone marrow biopsy  
 Screening visit note  
 Signed informed consent document 
 HIPAA authorization form (if separate from the informed consent document)  
 Eligibility Checklist  
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
61 DF/HCC Biomedical Protocol Template 
Version: July 17, [ADDRESS_508917] should be filled out by a clinical  study staff member and the 
“Screening Staff” section must be signed by [CONTACT_476].  Study staff at the Coordinating 
Center will review the eligib ility documentation and sign as  the “Enrollm ent Monitor.” 
 The Coordinating Center  will review the submitted doc uments in order to verify 
eligibility and consent. To complete the registration pro cess, the Coordinator will follow 
DF/HCC Standard Operating Procedure for Human Subject Research Titled Subject 
Protocol Registration (SOP #: REGIST-101B) and register  the participant on the protocol 
in OnCore.  The coordinator will fax or e-mail the participant study number, and if 
applicable the dose treatment level, to the par ticipating site.  The coordinator will also call 
the research nurse or data manager at th e participating site and verbally confirm 
registration  
 
Treatment may not begin without confir mation from the Coordinating Center 
that the participant has been registered.  
 Randomization can only occur during normal business hours, Monday through Friday from 8:00 AM to 5:[ADDRESS_508918] be registered with th e DF/HCC ODQ before re ceiving treatment.  
Treatment may not be initiated until the Participating Institu tion receives confirmation of 
the participant’s registration from the C oordinating Center. The DF/HCC Sponsor and 
DFCI IRB must be notified of a ny violations to this policy. 
 
17.7.3   Eligibility Exceptions 
 
The DF/HCC ODQ will make no exceptions to th e eligibility requirements for a protocol 
without DFCI IRB approval. The DF/HCC ODQ re quires each institution to fully comply 
with this requirement. 
 
17.8 DF/HCC Protocol Case Number 
 
At the time of registration, ODQ/OnCore require s the following identifiers for all subjects: 
initials, date of birth, gender,  race and ethnicity. Once eligibility has been established and 
the participant successfully registered, the pa rticipant is assigned a unique protocol case 
number.  Participating Institutions shoul d submit all de-identified subsequent 
communication and documents to the Coordinating Center, using this case number to identify the subject.   
 
17.8.1  Protocol Deviations, Exceptions and Violations 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
62 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Federal Regulations require an IRB to review proposed change s in a research activity to 
ensure that researchers do not initiate cha nges in approved research without IRB review 
and approval, except when necessary to el iminate apparent immediate hazards to the 
participant. DF/HCC requires all departures fr om the defined procedures set forth in the 
IRB approved protocol to be reported to the DF/HCC Sponsor, who in turn is responsible 
for reporting to the DFCI IRB. 
  For reporting purposes, DF/HCC uses the terms “violation”, “deviation” and “exception” 
to describe departures from a protocol. All Participating Inst itutions must adhere to these 
requirements for reporting to the DF/HCC Sp onsor and will follow their institutional 
policy for reporting to their local IRB. 
 
17.8.2   Definitions 
 
Protocol Deviation: Any departure from th e defined procedures set forth in the IRB-
approved protocol which is prospectively approved  prior to its implementation. 
 Protocol Exception:  Any protoc ol deviation that relates to the eligibility criteria, e.g. 
enrollment of a participant who does not meet all inclusion/exclusion criteria. 
   Protocol Violation: Any prot ocol deviation that was not prospectively approved  by [CONTACT_221855].   
 
17.8.3   Reporting Procedures 
 
DF/HCC Sponsor: is responsible for ensuring that clear docume ntation is available in the 
medical record and/or regulatory documents to describe all protocol exceptions, deviations 
and violations. The DF/HCC Sponsor will al so be responsible fo r ensuring that all 
protocol violations/deviati ons are promptly reported per DFCI IRB guidelines.  
 Participating Institutions: Protocol deviations  require prospective approval from the DFCI 
IRB. The Participating Institution must subm it the deviation request to the Coordinating 
Center who will then submit the deviation request to the DFCI IRB. Upon DFCI IRB 
approval the deviation is submitted to the Par ticipating Institution IRB, per institutional 
policy. A copy of the Participating Institut ion’s IRB report and determination will be 
forwarded to the Coordinating Center with in [ADDRESS_508919] be sent to the Coordinating Center in a timely manner.  
 Coordinating Center:  Upon receipt of the viol ation/deviation report fr om the Participating 
Institution, the Coordinating Center will s ubmit the report to the DF/HCC Sponsor for 
review. Subsequently, the Participating Institu tion’s IRB violation/deviation report will be 
submitted to the DFCI IRB for review per DFCI IRB reporting guidelines. DF/HCC will 
forward all violation reports to CTEP via an  internal DF/HCC process, as applicable. 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
63 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 17.9 Safety Assessments and Toxicity Monitoring 
 
The study teams at all particip ating institutions ar e responsible for protecting the safety, 
rights and well-being of study par ticipants. Recording and repor ting of adverse events that 
occur during the course of a study help ensure the continuing safety of study participants.  
 All participants receiving investigational agen ts and/or other protoc ol mandated treatment 
will be evaluated for safety. The safety parameters include all laboratory tests and hematological abnormalities, physical examin ation findings, and spont aneous reports of 
adverse events reported by [CONTACT_4317].  A ll toxicities encountered during the study will 
be evaluated according to the NCI criteria sp ecified in the protocol. Life-threatening 
toxicities must be reported immediately to the DF/HCC Sponsor via the Coordinating 
Center.  
 
Additional safety assessments and toxicity monitoring will be outlined in the protocol. 
 
17.9.1  Guidelines for Reporting Serious Adverse Events  
 
Guidelines for reporting Adverse Events (A Es) and Serious Adverse Events (SAEs) are 
detailed in protocol section 7.      
 Participating Institutions must report the SAEs to the DF/HCC Sponsor and the 
Coordinating Center following the DFCI IRB Adverse Event Reporting Policy .  
 
The Coordinating Center will maintain documentation of all Participating Institution Adverse Event reports and be responsible  for communicating to all participating 
investigators, any observations reportable under the DFCI IRB Repor ting Requirements.  
Participating Institutions will review and submit to their IRB according to their 
institutional policies and procedures 
 
 
17.9.2  Guidelines for Processing IND Safety Reports  
 
The DF/HCC Sponsor will review all IND Safety  Reports and ensure that all IND Safety 
Reports are distributed to the Participating Institutions. Participating Institutions will 
review and submit to their IRB according to their institutional policies and procedures.   
  
17.10  
Data Management 
 
The DF/HCC CTRIO develops case report forms (CRF/eCRFs), for use with the protocol.  
These forms are designed to collect data for each study. The DF/HCC CTRIO provides a 
web based training for eCRF users. 
   
17.10.1  Data Forms Review 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
64 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 Data submissions are monitored for time liness and completeness of submission. 
Participating Institutions are no tified of their data submissi on delinquencies in accordance 
with the following:  Incomplete or Questionable Data 
If study forms are received with missing or questionable data, the submitting institution 
will receive a written or el ectronic query from the DF/HCC CTRIO Data Analyst, 
Coordinating Center or desi gnee.  Responses to  all queries should  be completed and 
submitted within 14 calendar days.  Responses ma y be returned on the written query or on 
an amended paper case report form, or in th e case of electronic queries, within the 
electronic data capture (eDC) system. In the ca se of a written query for data submitted on 
a paper case report form, the query must be attached to the specific data being re-
submitted in response.    Missing Forms 
If study forms are not submitted on schedule, th e Participating Institution will receive a 
Missing Form Report from the Coordinating Center noting the missing forms.  These reports are compi[INVESTIGATOR_163871]/HCC QACT a nd distributed on a monthly basis.  
 
18. 
REQUISITIONING INVESTIGATIONAL DRUG 
  
The ordering of investigational agent is specified in the protocol section 8.1.6.  
 Participating Institutions s hould order their own agent re gardless of the supplier.  
 If the agent is investigational, ensure that th e pharmacy will be able to receive and store the 
agent according to state and federal requirement s. The local IRB should be kept informed 
of who will supply the agent so that any regul atory responsibilities can be met in a timely 
fashion.  
 
19. 
MONITORING: QUALITY CONTROL 
 
 
The quality control process for a clinical trial requires verification of protocol compliance 
and data accuracy. The Coordinating Center , with the aid of th e ODQ provides quality 
control oversight for the protocol. 
 
19.[ADDRESS_508920] itutions are complying with regulatory and 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
65 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 protocol requirements, data quality, and par ticipant safety. Monitoring will occur before 
the clinical phase of the protocol begins , continue during prot ocol performance and 
through study completion. Additional monitoring practices may include but are not limited 
to; source verification, review and analysis of the following: eligibility  requirements of all 
participants, informed consent procedur es, adverse events and all associated 
documentation, study drug administration/treatment, regulatory files, protocol departures, 
pharmacy records, response assessments, and data management.   Additionally, regular and ongoing communication with Pa rticipating Institutions will be 
accomplished by [CONTACT_403482] [ADDRESS_508921] as needed for significant events (i.e. change in accrual, 
event involving participant, etc.)  The Lead Institution will keep in close touch with the Participating Institutions via email and phone. Source documents from Participating 
Institutions, will be collected at specific data points that support the primary and or 
 
Remote Monitoring 
 Participating Institutions will be required to forward de-identified copi[INVESTIGATOR_57912]’ 
medical record and source documents to the Coordinating Center to aid in source data 
verification.  Each participant’s initial cons ent and eligibility will be reviewed within [ADDRESS_508922] annual on-site visits to for a Pharmacy site review, 
Regulatory binder review, and to meet w ith the site PI (if available).   
 Closeout Monitoring 
 Closeout monitoring will be done re motely at the end of the study.  
 
 
19.2 Monitoring Reports 
 
The DF/HCC Sponsor will review all monitoring reports for on-site and remote monitoring of Participating Institutions to ensure protocol compliance. The DF/HCC 
Sponsor may increase the monitoring activities at  Participating Institu tions that are unable 
to comply with the protocol, DF/HCC S ponsor requirements or federal and local 
regulations. Participating Institutions may also be subject to an audit as determined by [CONTACT_57954]/HCC Sponsor. 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
66 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 19.3 Accrual Monitoring 
 
Prior to extending a protocol to an external  site, the DF/HCC Sponsor will establish 
accrual requirements for each participating inst itution. Accrual will be monitored for each 
participating institution by [CONTACT_57954]/HCC Sponsor  or designee. Sites that are not meeting 
their accrual expectations may be subject to termination. Due to the small patient 
population, the accrual minimum requirement is  at least 1 patient every two years. 
 
20. AUDITING: QUALITY ASSURANCE 
 
Auditing is a method of Quality Assurance. Its main focus is to measure whether standards 
and procedures were followed. Auditing is the systematic and independent examination of 
all trial related activities and documents.  Au dits determine if evaluated activities were 
appropriately conducted and whether data wa s generated, recorded and analyzed, and 
accurately reported per the protocol, Standard Operating Procedures (SOPs), and the Code 
of Federal Regulations (CFR). 
 
 
20.1 Audit Plan: DF/HCC Sponsored Trials 
 
One on-site audit will be scheduled by [CONTACT_313867], a ssuming at least three participants have 
been treated on protocol at the site. Approxima tely 3-[ADDRESS_508923] participant safety or the integrity 
of the study are found, more partic ipant records may be audited.  
 
20.2 Audit Notification 
 
It is the Participating Institution’s responsibil ity to notify the Coordinating Center of all 
scheduled audit dates (interna l or NCI) and re-audit dates (if applicable), which involve 
this protocol. All institutions will forward a c opy of final audit and/ or re-audit reports and 
corrective action plans (if applicable) to th e Coordinating Center, within 12 weeks after 
the audit date.  
 
20.3 Audit Reports  
 
The DF/HCC Sponsor will review  all final audit reports and corrective action plans if 
applicable. The Coordinating Ce nter, must forward these re ports to the DF/HCC ODQ per 
DF/HCC policy for review by [CONTACT_57954]/HCC  Audit Committee. Based upon the audit 
assessments the DF/HCC Audit Committee c ould accept or conditionally accept the audit 
rating and final report. Conditional approva l could require the DF/HCC Sponsor to 
implement recommendations or require furt her follow-up.  For unacceptable audits, the 
DF/HCC Audit Committee would forward the fina l audit report and co rrective action plan 
to the DFCI IRB as applicable. 
 
20.4 Participating Instit ution Performance 
 
NCI Protocol #: N/a 
DF/HCC Protocol #:15-491  
Protocol Version Date:1/18/18 
 
67 DF/HCC Biomedical Protocol Template 
Version: July 17, 2015 The DF/HCC Sponsor, DFCI IRB, is charge d with considering th e totality of an 
institution’s performance in considering institutional participation in the protocol. 
 
20.[ADDRESS_508924] been corrected, as evidenced by [CONTACT_57955]. Particip ating Institutions that fail to demonstrate significant 
improvement will be considered by [CONTACT_57954]/HCC Sponsor for revocation of participation. 
A DF/HCC Sponsor and/or the DFCI IRB may terminate a site’s participation if it is 
determined that a site is not fulfilling its responsibilities as described above. 
    
    